

CITATION REPORT

List of articles citing

Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database

DOI: 10.1136/ard.2009.114264

Annals of the Rheumatic Diseases, 2010, 69, 1809-15.

Source: <https://exaly.com/paper-pdf/49274227/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
877	Infiltrative lung diseases in pregnancy. 2011 , 32, 133-146		10
876	The role of regional and neuroaxial anesthesia in patients with systemic sclerosis. 2011 , 4, 47-56		4
875	Hematopoietic stem cell transplantation for systemic sclerosis: history and current status. 2011 , 23, 519-29		13
874	Biological treatments and connective tissue disease associated interstitial lung disease. 2011 , 17, 362-7		45
873	Current world literature. 2011 , 23, 620-5		
872	Systemic sclerosis and the heart: current diagnosis and management. 2011 , 23, 545-54		64
871	[Acute cardiomyopathy as a clinical manifestation of systemic sclerosis]. 2011 , 211, e51-3		2
870	Imatinib and the treatment of fibrosis: recent trials and tribulations. 2011 , 13, 51-8		21
869	Left ventricular dysfunction assessed by speckle-tracking strain analysis in patients with systemic sclerosis: relationship to functional capacity and ventricular arrhythmias. 2011 , 63, 3969-78		59
868	Registries in systemic sclerosis: a worldwide experience. 2011 , 50, 60-8		31
867	Primary biliary cirrhosis associated with systemic sclerosis: diagnostic and clinical challenges. 2011 , 2011, 976427		32
866	Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 104-9	2.4	144
865	Ethnic differences in cardiovascular risk in rheumatic disease: focus on Asians. 2011 , 7, 609-18		8
864	Outcomes of Barrett's oesophagus related to systemic sclerosis: a 3-year EULAR Scleroderma Trials and Research prospective follow-up study. 2011 , 50, 1440-4		51
863	Survival is improving in systemic sclerosis: true or false?. 2012 , 51, 959-61		4
862	Malnutrition in systemic sclerosis. 2012 , 51, 1747-56		41
861	The impact of cardiopulmonary manifestations on the mortality of SSc: a systematic review and meta-analysis of observational studies. 2012 , 51, 1027-36		79

860	Investigation of prognostic factors for skin sclerosis and lung function in Japanese patients with early systemic sclerosis: a multicentre prospective observational study. 2012 , 51, 129-33		12
859	Optimization of autologous stem cell transplantation for systemic sclerosis -- a single-center longterm experience in 26 patients with severe organ manifestations. 2012 , 39, 269-75		42
858	Abstracts of the 34th Scandinavian Congress of Rheumatology. Copenhagen, Denmark. September 2-5, 2012. 2012 , 126, 1-68		
857	Renal disease in scleroderma: an update on evaluation, risk stratification, pathogenesis and management. 2012 , 24, 669-76		62
856	Innovative antifibrotic therapies in systemic sclerosis. 2012 , 24, 274-80		43
855	Survival, causes of death, and prognostic factors in systemic sclerosis: analysis of 947 Brazilian patients. 2012 , 39, 1971-8		70
854	Differences in virus prevalence and load in the hearts of patients with idiopathic dilated cardiomyopathy with and without immune-mediated inflammatory diseases. 2012 , 19, 1182-7		18
853	Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. 2012 , 51, 1017-26		260
852	Circulating biomarkers of interstitial lung disease in systemic sclerosis. 2012 , 2012, 121439		18
851	IRF5 polymorphism predicts prognosis in patients with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1197-202	2.4	66
850	Auto-HSCT induces sustained responses in severe systemic sclerosis patients failing pulse cyclophosphamide. 2012 , 47, 1486-7		8
849	Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers. 2012 , 24, 165-70		203
848	Systemic sclerosis. 2012 , 73, 509-10, 511-6		5
847	Two-dimensional speckle tracking of the left ventricle in patients with systemic sclerosis for an early detection of myocardial involvement. 2012 , 13, 863-70		41
846	Heart transplantation in a 36-year-old experiencing terminal heart failure caused by systemic sclerosis. 2012 , 94, e13-5		14
845	Imaging modalities for the diagnosis of pulmonary hypertension in systemic sclerosis. 2012 , 8, 203-13		26
844	Complications of autologous hematopoietic stem cell transplantation for patients with autoimmune diseases. 2012 , 71, 439-44		43
843	Pulmonary echography in systemic sclerosis. 2012 , 31, 1621-5		24

842	Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group. 2012 , 64, 1405-14	72
841	JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor β in systemic sclerosis. 2012 , 64, 3006-15	89
840	Is there evidence for vasculitis in systemic sclerosis?. 2012 , 14, 516-25	10
839	Principles of Management. 2012 , 571-576	
838	Cardiac Involvement. 2012 , 373-393	1
837	Epidemiology and Environmental Risk Factors. 2012 , 17-28	2
836	Clinical Assessment of Lung Disease. 2012 , 403-413	
835	Overview: Gastrointestinal Manifestations and Management. 2012 , 463-469	
834	Can We Predict the Severity of Pulmonary Hypertension in Patients With Scleroderma?. 2012 , 8, 259-262	
833	Can we predict the severity of pulmonary hypertension in patients with scleroderma?. 2012 , 8, 259-62	4
832	N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study. 2012 , 14, R143	65
831	Pulmonary arterial hypertension therapy may be safe and effective in patients with systemic sclerosis and borderline pulmonary artery pressure. 2012 , 64, 1257-62	47
830	Inhibition of activator protein 1 signaling abrogates transforming growth factor β -mediated activation of fibroblasts and prevents experimental fibrosis. 2012 , 64, 1642-52	65
829	Fertilitätsprotektion bei rheumatologischen Erkrankungen. 2012 , 10, 105-109	
828	Scleroderma - new aspects in pathogenesis and treatment. 2012 , 26, 13-24	34
827	Incidence rate and causes of infection in Thai systemic sclerosis patients. 2012 , 15, 277-83	7
826	Rapidly progressive systemic sclerosis associated with breast carcinoma: report of a case with anti-RNA polymerase III antibody. 2012 , 39, 574-6	2
825	The six-minute walk test in scleroderma: what should we measure and how should we measure it?. 2012 , 17, 588-9	7

824	Genetics of scleroderma: implications for personalized medicine?. 2013 , 11, 9	33
823	Clinical aspects of autoimmune rheumatic diseases. 2013 , 382, 797-808	130
822	Update on stem cell transplantation for systemic sclerosis: recent trial results. 2013 , 15, 326	19
821	Proteinuria in systemic sclerosis: reversal by ACE inhibition. 2013 , 33, 2225-30	5
820	My approach to the treatment of scleroderma. 2013 , 88, 377-93	42
819	Update on the etiopathogenesis of systemic sclerosis. 2013 , 53, 516-524	1
818	Updated clinical classification of pulmonary hypertension. 2013 , 62, D34-41	1937
817	Enteric-coated mycophenolate sodium for progressive systemic sclerosis--a prospective open-label study with CT histography for monitoring of pulmonary fibrosis. 2013 , 32, 673-8	12
816	Borderline mean pulmonary artery pressure in patients with systemic sclerosis: transpulmonary gradient predicts risk of developing pulmonary hypertension. 2013 , 65, 1074-84	107
815	Soluble CD90 as a potential marker of pulmonary involvement in systemic sclerosis. 2013 , 65, 281-7	12
814	Correlation of interferon-inducible chemokine plasma levels with disease severity in systemic sclerosis. 2013 , 65, 226-35	61
813	Does C-reactive protein predict the long-term progression of interstitial lung disease and survival in patients with early systemic sclerosis?. 2013 , 65, 1375-80	71
812	Epidemiolog ^ı de las enfermedades reum ^ı icas. 2013 , 46, 1-16	
811	Targeted therapies for systemic sclerosis. 2013 , 9, 451-64	24
810	Performance of screening algorithms in systemic sclerosis-related pulmonary arterial hypertension: a systematic review. 2013 , 43, 751-60	9
809	Endocardial and myocardial involvement in systemic sclerosis--is there a relevant inflammatory component?. 2013 , 80, 320-3	23
808	Mortality in systemic sclerosis-a single centre study from the UK. 2013 , 32, 1533-9	37
807	Indications for hospitalization and in-hospital mortality in Thai systemic sclerosis. 2013 , 32, 361-7	14

806	Lactulose breath test to assess oro-cecal transit delay and estimate esophageal dysmotility in scleroderma patients. 2013 , 42, 522-9	23
805	Canonical Wnt signalling as a key regulator of fibrogenesis - implications for targeted therapies?. 2013 , 22, 710-3	39
804	Low socioeconomic status (measured by education) and outcomes in systemic sclerosis: data from the Canadian Scleroderma Research Group. 2013 , 40, 447-54	14
803	Skin gene expression correlates of severity of interstitial lung disease in systemic sclerosis. 2013 , 65, 2917-27	28
802	Survival and causes of death in an unselected and complete cohort of Norwegian patients with systemic sclerosis. 2013 , 40, 1127-33	35
801	Scleroderma lung disease. 2013 , 22, 6-19	158
800	Perioperative Management of the Patient with Pulmonary Hypertension. 2013 , 137-154	1
799	Is vasculopathy associated with systemic sclerosis more severe in men?. 2013 , 40, 46-51	12
798	Can serum surfactant protein D or CC-chemokine ligand 18 predict outcome of interstitial lung disease in patients with early systemic sclerosis?. 2013 , 40, 1114-20	46
797	The ambitious goal of validating prognostic biomarkers for systemic sclerosis-related interstitial lung disease. 2013 , 40, 1034-6	4
796	Current status of systemic sclerosis biomarkers: applications for diagnosis, management and drug development. 2013 , 9, 1077-90	30
795	Ischemic arterial events and atherosclerosis in patients with systemic sclerosis: a population-based case-control study. 2013 , 15, R87	47
794	Survival in systemic sclerosis with pulmonary arterial hypertension has not improved in the modern era. 2013 , 144, 1282-1290	55
793	Influence of interstitial lung disease on outcome in systemic sclerosis: a population-based historical cohort study. 2013 , 144, 571-577	27
792	^bid^ miologie des maladies rhumatismales. 2013 , 8, 1-15	5
791	Augmented in vitro expression of CCL2 by peripheral blood mononuclear cells is associated with the presence of interstitial lung disease in patients with systemic sclerosis. 2013 , 3, 179-184	
790	Muscle RING finger-1 promotes a maladaptive phenotype in chronic hypoxia-induced right ventricular remodeling. 2014 , 9, e97084	5
789	Electrocardiography in 110 patients with systemic sclerosis: a cross-sectional comparison with population-based controls. 2014 , 43, 221-5	17

788	Borderline pulmonary arterial pressure in systemic sclerosis patients: a post-hoc analysis of the DETECT study. 2014 , 16, 493		36
787	Potential role of the lectin pathway of complement in the pathogenesis and disease manifestations of systemic sclerosis: a case-control and cohort study. 2014 , 16, 480		15
786	Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. 2014 , 69, 428-36		75
785	The effect of male sex on survival in systemic sclerosis. 2014 , 41, 2193-200		40
784	Derivation and validation of a prediction rule for two-year mortality in early diffuse cutaneous systemic sclerosis. 2014 , 66, 1616-24		29
783	Prediction of pulmonary complications and long-term survival in systemic sclerosis. 2014 , 66, 1625-35		249
782	Atherosclerotic cardiovascular disease in hospitalized patients with systemic sclerosis: higher mortality than patients with lupus and rheumatoid arthritis. 2014 , 66, 323-7		26
781	Prevalence and causes of loss to follow-up among patients with systemic sclerosis. 2014 , 20, 456		3
780	The primary care physician in the early diagnosis of systemic sclerosis: the cornerstone of recognition and hope. 2014 , 347, 54-63		16
779	Is atherosclerosis accelerated in systemic sclerosis? Novel insights. 2014 , 26, 653-7		21
778	Mortality in systemic sclerosis: lessons learned from population-based and observational cohort studies. 2014 , 26, 131-7		41
777	Evaluation and management of gastrointestinal manifestations in scleroderma. 2014 , 26, 621-9		28
776	Inactivation of urokinase-type plasminogen activator receptor (uPAR) gene induces dermal and pulmonary fibrosis and peripheral microvasculopathy in mice: a new model of experimental scleroderma?. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1700-9	2.4	65
775	Pictorial review of intrathoracic manifestations of progressive systemic sclerosis. 2014 , 9, 193-202		4
774	Reconciling healthcare professional and patient perspectives in the development of disease activity and response criteria in connective tissue disease-related interstitial lung diseases. 2014 , 41, 792-8		36
773	Five-year follow-up of left ventricular diastolic function in systemic sclerosis patients: determinants of mortality and disease progression. 2014 , 44, 220-7		28
772	Relationship between body composition and both cardiovascular risk factors and lung function in systemic sclerosis. 2014 , 33, 77-82		6
771	Abnormal cardiac enzymes in systemic sclerosis: a report of four patients and review of the literature. 2014 , 33, 435-8		9

770	Nutritional status measured by BMI is impaired and correlates with left ventricular mass in patients with systemic sclerosis. 2014 , 30, 204-9		16
769	Screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension: a systematic review. 2014 , 43, 536-41		15
768	Cognitive-behavioural therapy targeting fear of progression in an interdisciplinary care program: a case study in systemic sclerosis. 2014 , 21, 297-312		3
767	Autologous stem cell transplantation with thiotepa-based conditioning in patients with systemic sclerosis and cardiac manifestations. 2014 , 53, 919-22		25
766	Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1340-9	2.4	444
765	Cardiac arrhythmias and conduction defects in systemic sclerosis. 2014 , 53, 1172-7		58
764	Biomarkers in pulmonary arterial hypertension. 2014 , 11, 477-84		11
763	Association of Interferon- and transforming growth factor β -regulated genes and macrophage activation with systemic sclerosis-related progressive lung fibrosis. 2014 , 66, 714-25		122
762	Musculoskeletal involvement in systemic sclerosis. 2014 , 43, e315-28		20
761	Interstitial lung disease in systemic sclerosis. 2014 , 43, e329-43		31
760	Lung Transplantation for Scleroderma-related Lung Disease. 2014 , 3, 79-87		5
759	Pimobendan improves right ventricular myocardial contraction and attenuates pulmonary arterial hypertension in rats with monocrotaline-induced pulmonary arterial hypertension. 2014 , 41, 173-80		3
758	Faecal levels of calprotectin in systemic sclerosis are stable over time and are higher compared to primary Sjögren's syndrome and rheumatoid arthritis. 2014 , 16, R46		11
757	Scleroderma-polymyositis overlap syndrome versus idiopathic polymyositis and systemic sclerosis: a descriptive study on clinical features and myopathology. 2014 , 16, R111		35
756	Echocardiographic follow-up of patients with systemic sclerosis by 2D speckle tracking echocardiography of the left ventricle. 2014 , 12, 13		24
755	Ten years EULAR Scleroderma Research and Trials (EUSTAR): what has been achieved?. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 324-7	2.4	15
754	Systemic sclerosis evolution of disease pathomorphosis and survival. Our experience on Italian patients' population and review of the literature. 2014 , 13, 1026-34		63
753	Mortality and survival in systemic sclerosis: systematic review and meta-analysis. 2014 , 44, 208-19		169

752	Current therapies for the treatment of systemic sclerosis-related pulmonary arterial hypertension: efficacy and safety. 2014 , 13, 295-305	15
751	A prediction model for progressive disease in systemic sclerosis. 2015 , 1, e000113	4
750	Associations between circulating endostatin levels and vascular organ damage in systemic sclerosis and mixed connective tissue disease: an observational study. 2015 , 17, 231	21
749	Cost savings with a new screening algorithm for pulmonary arterial hypertension in systemic sclerosis. 2015 , 45, 1134-40	14
748	Brief Report: Pulmonary Function Tests: High Rate of False-Negative Results in the Early Detection and Screening of Scleroderma-Related Interstitial Lung Disease. 2015 , 67, 3256-61	98
747	Registry of the Spanish Network for Systemic Sclerosis: Survival, Prognostic Factors, and Causes of Death. 2015 , 94, e1728	56
746	Causes and prevalence of inadequate pulmonary function testing among patients with systemic sclerosis. 2015 , 11, 1255-60	6
745	Lupus Myocarditis: A Case-Control Study from China. 2015 , 128, 2588-94	29
744	Early stage lung cancer detection in systemic sclerosis does not portend survival benefit: a cross sectional study. 2015 , 10, e0117829	10
743	Management of Systemic-Sclerosis-Associated Interstitial Lung Disease. 2015 , 41, 439-57	35
742	Histamine inhibits differentiation of skin fibroblasts into myofibroblasts. 2015 , 463, 434-9	12
741	Long-term outcome of patients with systemic sclerosis requiring home parenteral nutrition. 2015 , 34, 991-6	10
740	Management of Crashing Patients with Pulmonary Hypertension. 2015 , 33, 623-43	2
739	Scl ^{er} odermie syst ^h mique [´] : progr ^h r ^h cents. 2015 , 82, 291-297	
738	Monitoring and Diagnostic Approaches for Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis. 2015 , 41, 489-506	8
737	Inhibition of casein kinase II reduces TGF β -induced fibroblast activation and ameliorates experimental fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 936-43	2.4 30
736	Value of systolic pulmonary arterial pressure as a prognostic factor of death in the systemic sclerosis EUSTAR population. 2015 , 54, 1262-9	19
735	Systemic sclerosis: Recent insights. 2015 , 82, 148-53	44

734	Contractile reserve in systemic sclerosis patients as a major predictor of global cardiac impairment and exercise tolerance. 2015 , 31, 529-36		10
733	Infection and Systemic Sclerosis. 2015 , 735-744		
732	Management of Scleroderma-Associated Pulmonary Involvement. 2015 , 1, 51-67		
731	Time-dependent and somatically acquired mitochondrial DNA mutagenesis and respiratory chain dysfunction in a scleroderma model of lung fibrosis. 2014 , 4, 5336		27
730	Connective tissue disease-associated pulmonary arterial hypertension. 2015 , 41, 295-313		13
729	The indirect costs of systemic autoimmune diseases, systemic lupus erythematosus, systemic sclerosis and sarcoidosis: a summary of 2012 real-life data from the Social Insurance Institution in Poland. 2015 , 15, 667-73		13
728	Operator-independent quantitative chest computed tomography versus standard assessment of interstitial lung disease related to systemic sclerosis: A multi-centric study. 2015 , 25, 724-30		14
727	Epidemiology and Disease Classification of Pulmonary Hypertension. 2015 , 21-35		1
726	[Systemic sclerosis. Current classification and diagnosis of organ involvement]. 2015 , 66, 599-603		1
725	Cardiomyopathy in murine models of systemic sclerosis. 2015 , 67, 508-16		29
724	Cardiac troponin testing in idiopathic inflammatory myopathies and systemic sclerosis-spectrum disorders: biomarkers to distinguish between primary cardiac involvement and low-grade skeletal muscle disease activity. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 795-8	2.4	54
723	Recent advances in the genetics of systemic sclerosis: toward biological and clinical significance. 2015 , 17, 21		21
722	Asymptomatic cardiac involvement in Thai systemic sclerosis: prevalence and clinical correlations with non-cardiac manifestations (preliminary report). 2015 , 54, 1616-21		18
721	Borderline pulmonary pressures in scleroderma - a 'pre-pulmonary arterial hypertension' condition?. 2015 , 17, 123		7
720	Early systemic sclerosis-opportunities for treatment. 2015 , 34, 1327-31		14
719	Cardiac biomarkers in systemic sclerosis: contribution of high-sensitivity cardiac troponin in addition to N-terminal pro-brain natriuretic peptide. 2015 , 67, 1022-30		48
718	Imaging of pulmonary involvement in rheumatic disease. 2015 , 41, 167-96		5
717	Thinking outside the box--The associations with cutaneous involvement and autoantibody status in systemic sclerosis are not always what we expect. 2015 , 45, 184-9		18

716	Esclerodermia sist^ mica. 2015 , 48, 1-15		1
715	Tumour-associated antigens in systemic sclerosis patients with interstitial lung disease: association with lung involvement and cancer risk. 2015 , 54, 1991-9		11
714	Assessment of the educational impact of an information leaflet on the knowledge of complications in systemic sclerosis. 2015 , 82, 373-5		2
713	^ Valuation de l'impact d'une brochure d'information sur la connaissance des complications dans la scl^ dermie syst^ hique. 2015 , 82, 342-343		
712	Predictive value of serial high-resolution computed tomography analyses and concurrent lung function tests in systemic sclerosis. 2015 , 67, 2205-12		86
711	Incidence of lung cancer in patients with systemic sclerosis treated with extracorporeal photopheresis. 2015 , 31, 175-83		4
710	Biomarkers in rheumatic diseases: how can they facilitate diagnosis and assessment of disease activity?. 2015 , 351, h5079		41
709	Left ventricular myocardial dysfunction and premature atherosclerosis in patients with axial spondyloarthritis. 2015 , 54, 292-301		26
708	Early detection of pulmonary arterial hypertension. 2015 , 12, 143-55		84
707	Sirt1 regulates canonical TGF-β signalling to control fibroblast activation and tissue fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 226-33	2.4	94
706	A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 163-9	2.4	68
705	Prevalence of Pulmonary Arterial Hypertension in Korean Adult Patients with Systemic Sclerosis: Result of a Pilot Echocardiographic Screening Study. 2016 , 24, 312-316		7
704	The Assessment of Tp-e Interval and Tp-e/QT Ratio in Patients With Systemic Sclerosis. 2016 , 31, 139-144		11
703	Aberrant expression of cytokine interleukin 9 along with interleukin 4 and interferon γ in connective tissue disease-associated interstitial lung disease: association with severity of pulmonary fibrosis. 2016 , 12, 101-6		12
702	Subsets in systemic sclerosis: one size does not fit all. 2016 , 1, 298-306		7
701	Emerging strategies for treatment of systemic sclerosis. 2016 , 1, 186-193		36
700	Prognostic Role of Ventricular Ectopic Beats in Systemic Sclerosis: A Prospective Cohort Study Shows ECG Indexes Predicting the Worse Outcome. 2016 , 11, e0153012		31
699	miR-155 in the progression of lung fibrosis in systemic sclerosis. 2016 , 18, 155		71

698	Exercise pulmonary haemodynamics predict outcome in patients with systemic sclerosis. 2016 , 48, 1658-1667	35
697	To stress or not to stress? Exercise pulmonary haemodynamic testing in systemic sclerosis. 2016 , 48, 1549-1552	3
696	Multicentre randomised placebo-controlled trial of oral anticoagulation with apixaban in systemic sclerosis-related pulmonary arterial hypertension: the SPHInX study protocol. 2016 , 6, e011028	9
695	Clinical correlates of faecal incontinence in systemic sclerosis: identifying therapeutic avenues. 2017 , 56, 581-588	11
694	Primary myocardial disease in scleroderma-a comprehensive review of the literature to inform the UK Systemic Sclerosis Study Group cardiac working group. 2017 , 56, 882-895	13
693	Interstitial lung disease in systemic sclerosis: progress in screening and early diagnosis. 2016 , 28, 613-8	24
692	High Level of Chemokine CCL18 Is Associated With Pulmonary Function Deterioration, Lung Fibrosis Progression, and Reduced Survival in Systemic Sclerosis. 2016 , 150, 299-306	59
691	Baixos n ^o de níveis séricos de vitamina D na esclerose sistêmica difusa: correlação com pior qualidade de vida e alterações capilares graves. 2016 , 56, 337-344	5
690	Survival and causes of death in systemic sclerosis patients: a single center registry report from Iran. 2016 , 36, 925-34	11
689	The heart and pulmonary arterial hypertension in systemic sclerosis. 2016 , 71, 1-18	8
688	Predictors of inpatient mortality in patients with systemic sclerosis: a case control study. 2016 , 35, 1631-5	13
687	Clinical Trial Design Issues in Systemic Sclerosis: an Update. 2016 , 18, 38	8
686	Risk factors for malignancy in systemic sclerosis patients. 2016 , 35, 1529-33	14
685	Increased Periodontal Attachment Loss in Patients With Systemic Sclerosis. 2016 , 87, 763-71	16
684	Low vitamin D serum levels in diffuse systemic sclerosis: a correlation with worst quality of life and severe capillaroscopic findings. 2016 , 56, 337-44	13
683	A retrospective cohort study of outcome in systemic sclerosis-associated interstitial lung disease. 2016 , 54, 445-453	18
682	The Real Face of Borderline Pulmonary Hypertension in Connective Tissue Disease. 2016 , 13, 1428-30	5
681	Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. 2016 , 4, 708-719	487

680	Early morphologic and functional changes of atherosclerosis in systemic sclerosis-a systematic review and meta-analysis. 2016 , 55, 2119-2130	21
679	Patients with Systemic Sclerosis/polymyositis Overlap Have a Worse Survival Rate Than Patients Without It. 2016 , 43, 1838-1843	12
678	Survival and organ involvement in patients with limited cutaneous systemic sclerosis and anti-topoisomerase-I antibodies: determined by skin subtype or auto-antibody subtype? A long-term follow-up study. 2016 , 55, 2001-2008	19
677	Treatment of Systemic Sclerosis-related Interstitial Lung Disease: A Review of Existing and Emerging Therapies. 2016 , 13, 2045-2056	44
676	Quantitative chest CT analysis in patients with systemic sclerosis before and after autologous stem cell transplantation: comparison of results with those of pulmonary function tests and clinical tests. 2016 , 55, 1763-70	17
675	Scleroderma Lung Study II-clarity or obfuscation?. 2016 , 4, 678-679	2
674	Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies: A Scientific Statement From the American Heart Association. 2016 , 134, e579-e646	314
673	Central Hemodynamics and Arterial Stiffness in Systemic Sclerosis. 2016 , 68, 1504-1511	12
672	Aberrant immune response with consequent vascular and connective tissue remodeling - causal to scleroderma and associated syndromes such as Raynaud phenomenon and other fibrosing syndromes?. 2016 , 28, 571-6	
671	Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease. 2016 , 18, 305	42
670	Subclinical Atherosclerosis in Systemic Sclerosis: Not Less Frequent Than Rheumatoid Arthritis and Not Detected With Cardiovascular Risk Indices. 2016 , 68, 1538-46	16
669	Lung and gastrointestinal complications are leading causes of death in SCORE, a multi-ethnic Singapore systemic sclerosis cohort. 2016 , 45, 499-506	17
668	Cardiovascular risk and its modification in patients with connective tissue diseases. 2016 , 30, 81-94	9
667	Connective tissue disease-related pulmonary arterial hypertension. 2016 , 30, 22-38	26
666	Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patients. 2016 , 18, 20	13
665	OX40L blockade protects against inflammation-driven fibrosis. 2016 , 113, E3901-10	34
664	Derivation and External Validation of a Prediction Rule for Five-Year Mortality in Patients With Early Diffuse Cutaneous Systemic Sclerosis. 2016 , 68, 993-1003	24
663	Digital ulcers predict a worse disease course in patients with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 681-6	2.4 78

662	Risk factors for severity and manifestations in systemic sclerosis and prediction of disease course. 2016 , 12, 115-35		11
661	Biomarkers in Scleroderma: Progressing from Association to Clinical Utility. 2016 , 18, 17		11
660	Six-minute walk test in systemic sclerosis: A systematic review and meta-analysis. 2016 , 212, 265-73		21
659	The role of autologous haemopoietic stem cell transplantation in the treatment of autoimmune disorders. 2016 , 46, 17-28		11
658	Strategy for treatment of fibrosis in systemic sclerosis: Present and future. 2016 , 43, 46-55		28
657	Injury-Driven Stiffening of the Dermis Expedites Skin Carcinoma Progression. 2016 , 76, 940-51		75
656	Cellular Therapies in Systemic Sclerosis: Recent Progress. 2016 , 18, 12		17
655	The Application of Intravascular Ultrasound to Evaluate Pulmonary Vascular Properties and Mortality in Patients with Pulmonary Arterial Hypertension. 2016 , 29, 103-11		7
654	Systemic sclerosis and localized scleroderma--current concepts and novel targets for therapy. 2016 , 38, 87-95		61
653	Population-based analysis of hospitalizations for patients with systemic sclerosis in a West-European region over the period 2001-2012. 2016 , 36, 73-81		10
652	Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 883-90	2.4	120
651	Cardiac involvement in systemic sclerosis: differences between clinical subsets and influence on survival. 2017 , 37, 75-84		39
650	Regulatory T Cells in Systemic Sclerosis: a Comprehensive Review. 2017 , 52, 194-201		30
649	Development and validation of a patient-reported outcome instrument for skin involvement in patients with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1374-1380	2.4	15
648	Epidemiology and disease characteristics of systemic sclerosis-related pulmonary arterial hypertension: results from a real-life screening programme. 2017 , 19, 42		37
647	Systemic sclerosis. 2017 , 390, 1685-1699		764
646	Screening for pulmonary arterial hypertension in an unselected prospective systemic sclerosis cohort. 2017 , 49,		33
645	The fact not to ignore: Mean blood pressure is the main predictor of increased arterial stiffness in patients with systemic rheumatic diseases. 2017 , 62, 223-229		5

644	JAK1-dependent transphosphorylation of JAK2 limits the antifibrotic effects of selective JAK2 inhibitors on long-term treatment. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1467-1475	2.4	28
643	Severity and features of frailty in systemic sclerosis-associated interstitial lung disease. 2017 , 129, 1-7		13
642	Evaluation and management approaches for scleroderma lung disease. 2017 , 11, 327-340		13
641	Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial. 2017 , 18, 275		88
640	Multimodality Imaging in Restrictive Cardiomyopathies: An EACVI expert consensus document In collaboration with the "Working Group on myocardial and pericardial diseases" of the European Society of Cardiology Endorsed by The Indian Academy of Echocardiography. 2017 , 18, 1090-1121		58
639	Cardiopulmonary assessment of patients with systemic sclerosis for hematopoietic stem cell transplantation: recommendations from the European Society for Blood and Marrow Transplantation Autoimmune Diseases Working Party and collaborating partners. 2017 , 52, 1495-1503		62
638	Clinical algorithms for the diagnosis and prognosis of interstitial lung disease in systemic sclerosis. 2017 , 47, 228-234		28
637	Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II. 2017 , 69, 1451-1460		67
636	Lung Transplantation in Patients With Systemic Sclerosis. 2017 , 19, 23		14
635	Novel risk factors related to cancer in scleroderma. 2017 , 16, 461-468		30
634	Early Mortality in a Multinational Systemic Sclerosis Inception Cohort. 2017 , 69, 1067-1077		91
633	Na ⁺ deposition in the fibrotic skin of systemic sclerosis patients detected by ²³ Na-magnetic resonance imaging. 2017 , 56, 556-560		22
632	Points to consider when doing a trial primarily involving the heart. 2017 , 56, v12-v16		5
631	Pulmonary Hypertension and Thromboembolism—Long-Term Management and Chronic Oral Anticoagulation. 2017 , 2, 727-741		
630	Causes of death, survival and risk factors of mortality in Thai patients with early systemic sclerosis: inception cohort study. 2017 , 37, 2087-2094		13
629	Muscle involvement in systemic sclerosis: points to consider in clinical trials. 2017 , 56, v38-v44		19
628	Assessment of skin involvement in systemic sclerosis. 2017 , 56, v53-v66		32
627	Mapping and predicting mortality from systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1897-1905	2.4	230

626	Rituximab Experience in Patients With Long-standing Systemic Sclerosis-Associated Interstitial Lung Disease: A Series of 14 Patients. 2017 , 23, 411-415	21
625	Changes in pulmonary exercise haemodynamics in scleroderma: a 4-year prospective study. 2017 , 50,	20
624	Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review. 2017 , 53, 306-336	70
623	Risk factors and outcome of Thai patients with scleroderma renal crisis: a disease duration-matched case control study. 2017 , 20, 1562-1571	8
622	How I treat patients with systemic sclerosis in clinical practice. 2017 , 16, 1024-1028	16
621	Role of Stromelysin 2 (Matrix Metalloproteinase 10) as a Novel Mediator of Vascular Remodeling Underlying Pulmonary Hypertension Associated With Systemic Sclerosis. 2017 , 69, 2209-2221	14
620	Diagnosing and managing scleroderma-related pulmonary arterial hypertension. 2017 , 30, 11-18	1
619	Right ventricular longitudinal strain is diminished in systemic sclerosis compared with idiopathic pulmonary arterial hypertension. 2017 , 50,	25
618	RESSONÂNCIA MAGNÉTICA PARA DETECÇÃO DE ALTERAÇÕES CARDÍACAS EM PACIENTES COM ESCLEROSE SISTÊMICA PRECOCE: ESTUDO PILOTO. 2017 , 57, S100	
617	Systemic sclerosis: Choosing patients wisely when treating interstitial lung disease. 2017 , 13, 455-456	2
616	Malnutrition is an independent risk factor for mortality in Mexican patients with systemic sclerosis: a cohort study. 2017 , 37, 1101-1109	8
615	Survival and quality of life in incident systemic sclerosis-related pulmonary arterial hypertension. 2017 , 19, 122	33
614	Consensus best practice pathway of the UK Systemic Sclerosis Study group: management of cardiac disease in systemic sclerosis. 2017 , 56, 912-921	47
613	Screening auf pulmonale Hypertonie. 2017 , 14, 153-159	
612	Treatment of Interstitial Lung Disease. 2017 , 375-383	
611	Overview of Lung Involvement: Diagnosis, Differential Diagnosis and Monitoring. 2017 , 359-362	
610	Life-threatening arrhythmias in a scleroderma patient: the role of myocardial inflammation in arrhythmic outburst. 2017 , 46, 78-80	17
609	A critical view on cardiovascular risk in systemic sclerosis. 2017 , 37, 85-95	26

608	No changes in N-terminal pro-brain natriuretic peptide in a longitudinal cohort of patients with systemic sclerosis-associated pulmonary arterial hypertension on therapy with bosentan. 2017 , 20, 90-96	4
607	Prevalence and incidence of pulmonary arterial hypertension: 10-year follow-up of an unselected systemic sclerosis cohort. 2017 , 2, 196-202	7
606	The arachidonate 5-lipoxygenase activating protein gene polymorphism is associated with the risk of scleroderma-related interstitial lung disease: a multicentre European Scleroderma Trials and Research group (EUSTAR) study. 2017 , 56, 844-852	10
605	Managing Systemic Sclerosis-Related Interstitial Lung Disease in the Modern Treatment Era. 2017 , 2, 72-83	22
604	Tocilizumab Treatment of Patients with Systemic Sclerosis: Clinical Data. 2017 , 2, S29-S35	6
603	Systemic Sclerosis. 2017 , 301-326	
602	Clinical Features and Treatment of Scleroderma. 2017 , 1424-1460.e5	2
601	Environmental Pollution by Benzene and PM and Clinical Manifestations of Systemic Sclerosis: A Correlation Study. 2017 , 14,	9
600	Lung Infections in Systemic Rheumatic Disease: Focus on Opportunistic Infections. 2017 , 18,	19
599	The Australian Scleroderma Interest Group and database: 10 years of screening to save lives. 2017 , 206, 229	1
598	Predictors of lung function test severity and outcome in systemic sclerosis-associated interstitial lung disease. 2017 , 12, e0181692	44
597	Atherosclerosis and Cardiovascular Risk in Systemic Sclerosis. 2017 ,	3
596	Musculoskeletal Syndromes in Malignancy. 2017 , 2048-2065.e6	1
595	Extrahepatic Manifestations of Primary Biliary Cholangitis. 2017 , 11, 771-780	26
594	High prevalence of occupational exposure to solvents or silica in male systemic sclerosis patients: a Belgian cohort analysis. 2018 , 37, 1977-1982	14
593	CCL21 as a Potential Serum Biomarker for Pulmonary Arterial Hypertension in Systemic Sclerosis. 2018 , 70, 1644-1653	18
592	Diagnostic criteria, severity classification and guidelines of systemic sclerosis. 2018 , 45, 633-691	16
591	The ubiquitin proteasome system as a potential therapeutic target for systemic sclerosis. 2018 , 198, 17-28	6

590	Performance of the St George's Respiratory Questionnaire in patients with connective tissue disease-associated interstitial lung disease. 2018 , 23, 851		13
589	Cardiovascular involvement in systemic rheumatic diseases: An integrated view for the treating physicians. 2018 , 17, 201-214		28
588	Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis: A Systematic Review and Meta-Analysis. 2018 , 24, 937-944		25
587	The 6MWT as a prognostic tool in pulmonary arterial hypertension: results from the COMPERA registry. 2018 , 107, 460-470		18
586	Poly(ADP-ribose) polymerase-1 regulates fibroblast activation in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 744-751	2.4	27
585	Screening High-Resolution Computed Tomography of the Chest to Detect Interstitial Lung Disease in Systemic Sclerosis: A Global Survey of Rheumatologists. 2018 , 70, 971-972		24
584	Frequencies of borderline pulmonary hypertension before and after the DETECT algorithm: results from a prospective systemic sclerosis cohort. 2018 , 57, 480-487		21
583	The Four Corners Sign: A Specific Imaging Feature in Differentiating Systemic Sclerosis-related Interstitial Lung Disease From Idiopathic Pulmonary Fibrosis. 2018 , 33, 197-203		10
582	Disease staging and sub setting of interstitial lung disease associated with systemic sclerosis: impact on therapy. 2018 , 14, 127-135		5
581	Protein kinases G are essential downstream mediators of the antifibrotic effects of sGC stimulators. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 459	2.4	27
580	Lung transplantation for scleroderma lung disease: An international, multicenter, observational cohort study. 2018 , 37, 903-911		45
579	Lung transplantation in systemic sclerosis: A single center cohort study. 2018 , 85, 79-84		14
578	Elevated serum levels of sonic hedgehog are associated with fibrotic and vascular manifestations in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 626-628	2.4	10
577	Pulmonary manifestations in Egyptian patients with systemic sclerosis. 2018 , 40, 39-44		10
576	Do encourage your scleroderma patients at risk to get influenza vaccine. 2018 , 57, 1691-1692		
575	The histone demethylase Jumonji domain-containing protein 3 (JMJD3) regulates fibroblast activation in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 150-158	2.4	32
574	End-Stage Kidney Disease From Scleroderma in the United States, 1996 to 2012. 2018 , 3, 148-154		2
573	Capillary loss on nailfold capillary microscopy is associated with mortality in systemic sclerosis. 2018 , 37, 475-481		8

572	Expressions of p53 and PUMA in fibroblasts of systemic sclerosis patients are normal at transcription level. 2018 , 17, 549-554	2
571	Pulmonary arterial hypertension in the setting of scleroderma is different than in the setting of lupus: A review. 2018 , 134, 42-46	15
570	Malnutrition and sarcopenia in a large cohort of patients with systemic sclerosis. 2018 , 37, 987-997	37
569	Limited Exercise Capacity in Patients with Systemic Sclerosis: Identifying Contributing Factors with Cardiopulmonary Exercise Testing. 2018 , 45, 95-102	8
568	Determinants of mortality in systemic sclerosis: a focused review. 2018 , 38, 1847-1858	30
567	All-cause Healthcare Costs and Mortality in Patients with Systemic Sclerosis with Lung Involvement. 2018 , 45, 235-241	19
566	High Baseline Serum Clara Cell 16 kDa Predicts Subsequent Lung Disease Worsening in Systemic Sclerosis. 2018 , 45, 242-247	3
565	Complete heart block in systemic sclerosis: A case report and literature review. 2018 , 97, e13226	2
564	The role of nailfold videocapillaroscopy in patients with systemic sclerosis. 2018 , 41, 113-119	7
563	Serum concentration of surfactant protein D in patients with systemic sclerosis: The potential marker of the interstitial lung disease severity. 2018 , 32, 541-549	2
562	Outcomes of patients with systemic sclerosis treated with tocilizumab: Case series and review of the literature. 2018 , 32, 563-571	16
561	Trends in incidence, mortality, and causes of death associated with systemic sclerosis in Denmark between 1995 and 2015: a nationwide cohort study. 2018 , 2, 36	21
560	Hiperpigmentaci ^o ã y esclerosis cut ^o ãea de reciente aparici ^o ã. 2018 , 25, 281-285	
559	Relationship Between Ventricular Arrhythmias, Conduction Disorders, and Myocardial Fibrosis in Patients With Systemic Sclerosis. 2018 , 24, 25-33	10
558	Mortality and survival in systemic sclerosis: a review of recent literature. 2018 , 30, 588-593	21
557	Augmented concentrations of CX3CL1 are associated with interstitial lung disease in systemic sclerosis. 2018 , 13, e0206545	20
556	Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. 2018 , 27,	168
555	Patients with systemic sclerosis-associated pulmonary arterial hypertension express a genomic signature distinct from patients with interstitial lung disease. 2018 , 3, 242-248	8

554	Interleukin-33 in Systemic Sclerosis: Expression and Pathogenesis. 2018 , 9, 2663	5
553	Left Ventricular Diastolic Dysfunction Predicts Mortality in Patients With Systemic Sclerosis. 2018 , 72, 1804-1813	38
552	Diastolic Function in Systemic Sclerosis Patients: A Neglected Issue?. 2018 , 72, 1814-1816	1
551	Prognostic profile of systemic sclerosis: analysis of the clinical EUSTAR cohort in China. 2018 , 20, 235	17
550	Isolated DLco/VA reduction in systemic sclerosis patients: a new patient subset?. 2018 , 37, 3365-3371	1
549	Haemodynamics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension. 2018 , 52,	37
548	Mesenchymal Stromal Cells Based Therapy in Systemic Sclerosis: Rational and Challenges. 2018 , 9, 2013	24
547	Methyl-CpG-binding protein 2 mediates antifibrotic effects in scleroderma fibroblasts. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 1208-1218	2.4 25
546	Cardiac involvement in systemic sclerosis: identification of high-risk patient profiles in different patterns of clinical presentation. 2018 , 19, 393-395	4
545	Global longitudinal strain measured by speckle tracking identifies subclinical heart involvement in patients with systemic sclerosis. 2018 , 25, 1598-1606	20
544	Multispectral optoacoustic tomography of systemic sclerosis. 2018 , 11, e201800155	28
543	Neurologische Komplikationen der Kollagenosen. 2018 , 183-203	
542	Biomarkers for Pulmonary Vascular Remodeling in Systemic Sclerosis: A Pathophysiological Approach. 2018 , 9, 587	16
541	Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial. 2018 , 57, 2106-2113	101
540	Haematopoietic stem cell transplantation in systemic sclerosis. 2018 , 4, e000533	17
539	Circulating Protein Biomarkers in Systemic Sclerosis Related Pulmonary Arterial Hypertension: A Review of Published Data. 2018 , 5, 175	9
538	Immunotherapy of systemic sclerosis. 2018 , 14, 2559-2567	4
537	Subclinical cardiovascular disease and Systemic Sclerosis: A comparison between risk charts, quantification of coronary calcium and carotid ultrasonography. 2018 , 17, 900-905	7

536	Intravenous cyclophosphamide pulse therapy in interstitial lung disease associated with systemic sclerosis in a retrospective open-label study: influence of the extent of inflammation on pulmonary function. 2018 , 37, 2715-2722	14
535	Pandemic non-adjuvanted influenza A H1N1 vaccine in a cohort of patients with systemic sclerosis. 2018 , 57, 1721-1725	4
534	Update on assessment and management of primary cardiac involvement in systemic sclerosis.. 2018 , 3, 53-65	15
533	Decreased global myocardial perfusion at adenosine stress as a potential new biomarker for microvascular disease in systemic sclerosis: a magnetic resonance study. 2018 , 18, 16	14
532	Antibodies against chemokine receptors CXCR3 and CXCR4 predict progressive deterioration of lung function in patients with systemic sclerosis. 2018 , 20, 52	25
531	Relationship Between Ventricular Arrhythmias, Conduction Disorders, and Myocardial Fibrosis in Patients With Systemic Sclerosis: The Role of Cardiac Magnetic Resonance. 2019 , 25, e140-e141	1
530	Unmet Needs in Systemic Sclerosis Understanding and Treatment: the Knowledge Gaps from a Scientist's, Clinician's, and Patient's Perspective. 2018 , 55, 312-331	14
529	Vertebral fracture prevalence and measurement of the scanographic bone attenuation coefficient on CT-scan in patients with systemic sclerosis. 2018 , 38, 1901-1910	14
528	Hemodynamic and Histopathologic Benefits of Early Treatment with Macitentan in a Rat Model of Pulmonary Arterial Hypertension. 2018 , 48, 839-853	4
527	Mortality, length of stay and cost of hospitalization among patients with systemic sclerosis: results from the National Inpatient Sample. 2018 , 57, 1611-1622	15
526	Asiatic acid prevents the development of interstitial lung disease in a hypochlorous acid-induced mouse model of scleroderma. 2018 , 15, 8711-8716	4
525	Predictors of morbidity and mortality in early systemic sclerosis: Long-term follow-up data from a single-centre inception cohort. 2018 , 17, 816-820	23
524	The challenges and controversies of measuring disease activity in systemic sclerosis.. 2018 , 3, 115-121	7
523	Systemic Sclerosis at an Intensive Care Unit: A Case Series and Literature Review. 2019 , 25, 181-185	1
522	Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease. 2019 , 58, 567-579	35
521	Increased risk of mortality in systemic sclerosis-associated digital ulcers: a systematic review and meta-analysis. 2019 , 33, 405-409	8
520	Defining primary systemic sclerosis heart involvement: A scoping literature review. 2019 , 48, 874-887	16
519	Nailfold Videocapillaroscopy Changes Are Associated With the Presence and Severity of Systemic Sclerosis-Related Interstitial Lung Disease. 2019 , 25, e12-e15	8

518	Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases. 2019 , 38, 2673-2681		25
517	[Systemic sclerosis-clinical picture, diagnosis, and treatment]. 2019 , 70, 723-741		
516	Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1576-1582	2.4	18
515	Detection and Characterization of microRNAs and Their Target Genes in microRNA Microarray Datasets from Patients with Systemic Sclerosis-Interstitial Lung Disease. 2019 , 38, 933-944		5
514	Pulmonary Manifestations of Systemic Sclerosis and Mixed Connective Tissue Disease. 2019 , 40, 501-518		13
513	Hematopoietic Stem Cell Transplantation for Systemic Sclerosis: Review of Current Status. 2019 , 33, 401-409		8
512	Clinical and Echocardiographic Associates of All-Cause Mortality and Cardiovascular Outcomes in Patients With Systemic Sclerosis. 2019 , 12, 2273-2276		1
511	Comorbidity burden in systemic sclerosis: beyond disease-specific complications. 2019 , 39, 1507-1517		10
510	Reduced diffusing capacity for carbon monoxide predicts borderline pulmonary arterial pressure in patients with systemic sclerosis. 2019 , 39, 1883-1887		2
509	Performance of a new quantitative computed tomography index for interstitial lung disease assessment in systemic sclerosis. 2019 , 9, 9468		14
508	Impact of the revised haemodynamic definition on the diagnosis of pulmonary hypertension in patients with systemic sclerosis. 2019 , 54,		24
507	Safety and Tolerability of Thrombin Inhibition in Scleroderma-Associated Interstitial Lung Disease. 2019 , 1, 403-411		9
506	Incidental significant arrhythmia in scleroderma associates with cardiac magnetic resonance measure of fibrosis and hs-Tnl and NT-proBNP. 2019 , 58, 1221-1226		17
505	Is there today a place for corticosteroids in the treatment of scleroderma?. 2019 , 18, 102403		12
504	Clinical and laboratory predictions of myocardial inflammation as detected by cardiac magnetic resonance imaging in patients with systemic sclerosis: A pilot study. 2019 , 22, 2125-2133		0
503	Cardiovascular Manifestations of Systemic Sclerosis: A Danish Nationwide Cohort Study. 2019 , 8, e013405		27
502	Emerging Factors Implicated in Fibrotic Organ-Associated Thrombosis: The Case of Two Organs. 2019 , 3, e165-e170		2
501	Exosomes in Systemic Sclerosis: Messengers Between Immune, Vascular and Fibrotic Components?. 2019 , 20,		18

500	Screening and identification of biomarkers for systemic sclerosis via microarray technology. 2019 , 44, 1753-1770	4
499	Advances in Management of Pulmonary Hypertension Associated with Systemic Sclerosis. 2019 ,	1
498	Scleroderma-related interstitial lung disease: principles of management. 2019 , 13, 357-367	5
497	Intriguing Relationships Between Cancer and Systemic Sclerosis: Role of the Immune System and Other Contributors. 2018 , 9, 3112	34
496	Interstitial lung disease associated with systemic sclerosis (SSc-ILD). 2019 , 20, 13	80
495	Rapidly progressive endomyocardial fibrosis and heart failure in a 17-year-old female with limited cutaneous systemic sclerosis. 2019 , 48, 336-337	
494	Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18. 2019 , 71, 2059-2067	29
493	Contribution of pulmonary function tests (PFTs) to the diagnosis and follow up of connective tissue diseases. 2019 , 14, 17	24
492	Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease. 2019 , 11, 257-273	66
491	[Systemic sclerosis-clinical picture, diagnosis, and treatment]. 2019 , 78, 439-457	
490	Gastroesophageal Reflux and Serum Biomarkers in Systemic Sclerosis-Associated Interstitial Lung Disease: Comment on the Article by Elhai et al. 2019 , 71, 1203-1204	
489	Setting the international standard for longitudinal follow-up of patients with systemic sclerosis: a Delphi-based expert consensus on core clinical features. 2019 , 5, e000826	16
488	Treatment of Diffuse Cutaneous Systemic Sclerosis with Biologics, Small Molecules and Stem Cell Transplantation: What Is the Evidence to Date?. 2019 , 5, 104-114	
487	Rationale for the evaluation of nintedanib as a treatment for systemic sclerosis-associated interstitial lung disease.. 2019 , 4, 212-218	19
486	Lung Ultrasound as a Screening Method for Interstitial Lung Disease in Patients With Systemic Sclerosis. 2019 , 25, 304-307	15
485	Fibrosing interstitial lung diseases: knowns and unknowns. 2019 , 28,	92
484	Progression of Left Ventricular Myocardial Dysfunction in Systemic Sclerosis: A Speckle-tracking Strain Echocardiography Study. 2019 , 46, 405-415	7
483	Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 648-656	2.4 43

482	Autologous hematopoietic stem cell transplant for progressive diffuse systemic sclerosis: procedural success and clinical outcome in 5-year follow-up. 2019 , 57, 50-54		4
481	A potential new approach for treating systemic sclerosis: Dedifferentiation of SSc fibroblasts and change in the microenvironment by blocking store-operated Ca ²⁺ entry. 2019 , 14, e0213400		2
480	The natural history of progressive fibrosing interstitial lung diseases. 2019 , 20, 57		88
479	Interstitial Lung Disease in Systemic Sclerosis: Lessons Learned from Idiopathic Pulmonary Fibrosis. 2019 , 5, 127-146		
478	Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis. 2019 , 71, 1553-1570		31
477	"Only as an Ultimate Solution!". 2019 , 104, 13-15		
476	Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 979-987	2.4	95
475	Association of cardiac magnetic resonance-detected myocardial abnormalities with disease characteristics and brain natriuretic peptide levels in systemic sclerosis without cardiac symptoms. 2019 , 22, 1016-1022		1
474	Survival and prognosis factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and meta-analysis of the literature. 2019 , 21, 86		48
473	Microvascular heart involvement in systemic autoimmune diseases: The purinergic pathway and therapeutic insights from the biology of the diseases. 2019 , 18, 317-324		5
472	Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II. 2019 , 46, 1316-1325		18
471	Health-related quality of life in systemic sclerosis compared with other rheumatic diseases: a cross-sectional study. 2019 , 21, 61		20
470	Arrhythmia in systemic sclerosis: catheter ablation or not?. 2019 , 48, 517-518		1
469	Getting to the heart of the matter: detecting and managing cardiac complications in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1452-1453	2.4	2
468	Systemic Sclerosis Associated Interstitial Lung Disease: New Directions in Disease Management. 2019 , 6, 248		7
467	Cardiac complications in systemic sclerosis: early diagnosis and treatment. 2019 , 132, 2865-2871		9
466	Systemic Sclerosis, Polycythemia Vera, and JAK Pathway: Coincidence or Correlation?. 2019 , 27,		1
465	[Systemic sclerosis]. 2019 , 60, 1251-1269		4

464	Prognostic value of cardiopulmonary exercise testing in patients with systemic sclerosis. 2019 , 19, 230		10
463	High risk of gastrointestinal hemorrhage in patients with systemic sclerosis. 2019 , 21, 301		1
462	Interstitial Lung Disease in Systemic Sclerosis: Focus on Early Detection and Intervention. 2019 , 11, 283-307		11
461	Proposition of a novel animal model of systemic sclerosis induced by type V collagen in C57BL/6 mice that reproduces fibrosis, vasculopathy and autoimmunity. 2019 , 21, 278		9
460	Management of systemic sclerosis-associated interstitial lung disease. 2019 , 31, 241-249		38
459	Detection and classification of systemic sclerosis-related interstitial lung disease: a review. 2019 , 31, 553-560		4
458	Biomarkers in systemic sclerosis. 2019 , 31, 595-602		8
457	Inflammatory stays inflammatory: a subgroup of systemic sclerosis characterized by high morbidity and inflammatory resistance to cyclophosphamide. 2019 , 21, 262		4
456	Arterial stiffness correlates with progressive nailfold capillary microscopic changes in systemic sclerosis: results from a cross-sectional study. 2019 , 21, 253		8
455	Interstitial Lung Disease and Other Pulmonary Manifestations in Connective Tissue Diseases. 2019 , 94, 309-325		37
454	Serum levels of Krebs von den Lungen-6 as a promising marker for predicting occurrence and deterioration of systemic sclerosis-associated interstitial lung disease from a Chinese cohort. 2019 , 22, 108-115		7
453	Impact of EUSTAR standardized training on accuracy of modified Rodnan skin score in patients with systemic sclerosis. 2019 , 22, 96-102		4
452	Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 122-130	2.4	88
451	Relationship Between Increased Fecal Calprotectin Levels and Interstitial Lung Disease in Systemic Sclerosis. 2019 , 46, 274-278		6
450	Pulmonary arterial hypertension in systemic sclerosis: Diagnosis and treatment according to the European Society of Cardiology and European Respiratory Society 2015 guidelines.. 2019 , 4, 35-42		9
449	Molecular profile and proangiogenic activity of the adipose-derived stromal vascular fraction used as an autologous innovative medicinal product in patients with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 391-398	2.4	18
448	Performance of Candidate Serum Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease. 2019 , 71, 972-982		57
447	Casting a Spotlight on the Right Ventricle in Systemic Sclerosis. 2019 , 71, 662-663		2

446	Epigenetics of Systemic Sclerosis. 2019 , 505-528	
445	Association of skin hyperpigmentation disorders with digital ulcers in systemic sclerosis: Analysis of a cohort of 239 patients. 2019 , 80, 478-484	8
444	Scleroderma Systemic Sclerosis. 2019 , 743-755.e1	2
443	Cardiac troponin T and NT-proBNP as diagnostic and prognostic biomarkers of primary cardiac involvement and disease severity in systemic sclerosis: A prospective study. 2019 , 60, 46-53	29
442	Unexpected acute lymphocytic virus-negative myocarditis in a patient with limited cutaneous systemic sclerosis: a case report. 2019 , 48, 166-167	5
441	Pulmonary hypertension in Spanish patients with systemic sclerosis. Data from the RESCLE registry. 2019 , 38, 1117-1124	5
440	Severe gastrointestinal disease in very early systemic sclerosis is associated with early mortality. 2019 , 58, 636-644	18
439	Isoprostane in systemic sclerosis: A systematic review and meta-analysis. 2019 , 29, 470-475	3
438	Distinct mortality profile in systemic sclerosis: a death certificate study in Rio de Janeiro, Brazil (2006-2015) using a multiple causes of death analysis. 2019 , 38, 189-194	1
437	Longterm Efficacy and Safety of Monotherapy versus Combination Therapy in Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Retrospective RESCLE Registry Study. 2020 , 47, 89-98	7
436	Evaluation of left and right ventricle by two-dimensional speckle tracking echocardiography in systemic sclerosis patients without overt cardiac disease. 2020 , 39, 37-48	10
435	Scleroderma Renal Crisis: Risk Factors for an Increasingly Rare Organ Complication. 2020 , 47, 241-248	11
434	Response to: "Relationship Between Ventricular Arrhythmias, Conduction Disorders, and Myocardial Fibrosis in Patients With Systemic Sclerosis: the Role of Cardiac Magnetic Resonance" by De Luca Giacomo, Campochiaro Corrado, Cavalli Giulio, Dagna Lorenzo. 2020 , 26, e36-e37	
433	Prediction of organ involvement and survival in systemic sclerosis patients in the first 5 years from diagnosis.. 2020 , 5, 57-65	2
432	Combination therapy with bosentan and sildenafil for refractory digital ulcers and Raynaud's phenomenon in a 30-year-old woman with systemic sclerosis: Case report and literature review.. 2020 , 5, 159-164	
431	Availability of EuroQol-5-Dimensions-5-Level (EQ-5D-5L) as health-related QOL assessment for Japanese systemic sclerosis patients. 2020 , 30, 681-686	3
430	T1 mapping cardiac magnetic resonance imaging frequently detects subclinical diffuse myocardial fibrosis in systemic sclerosis patients. 2020 , 50, 128-134	9
429	Abnormal electrophysiological testing associates with future incidental significant arrhythmia in scleroderma. 2020 , 59, 899-900	4

428 Systemic Sclerosis (Scleroderma). **2020**, 575-605

427 Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme. **2020**, 21, 7 8

426 Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease. **2020**, 201, 650-660 41

425 Effect of mycophenolate mofetil (MMF) on systemic sclerosis-related interstitial lung disease with mildly impaired lung function: a double-blind, placebo-controlled, randomized trial. **2020**, 40, 207-216 9

424 Natural History of Systemic Sclerosis-Related Interstitial Lung Disease: How to Identify a Progressive Fibrosing Phenotype. **2020**, 5, 31-40 16

423 [Treatment of systemic sclerosis-associated interstitial lung disease]. **2020**, 79, 294-303 2

422 Survival Improved in Patients Aged \geq 70 Years With Systemic Sclerosis-Associated Pulmonary Arterial Hypertension During the Period 2006 to 2017 in France. **2020**, 157, 945-954 5

421 Cardiac magnetic resonance predicts ventricular arrhythmias in scleroderma: the Scleroderma Arrhythmia Clinical Utility Study (SAnCtUS). **2020**, 59, 1938-1948 16

420 The clinical and economic burden of systemic sclerosis related interstitial lung disease. **2020**, 59, 1878-1888 4

419 Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD). **2020**, 11, 1990 4

418 Increased levels of HE4 (WFDC2) in systemic sclerosis: a novel biomarker reflecting interstitial lung disease severity?. **2020**, 11, 2040622320956420 4

417 Treatment of systemic sclerosis-associated interstitial lung disease: A systematic literature review and meta-analysis. **2020**, 27, 146-169

416 Current immunosuppressive and antifibrotic therapies of systemic sclerosis and emerging therapeutic strategies. **2020**, 13, 1203-1218 1

415 Systemic sclerosis: Update for oral health care providers. **2020**, 40, 418-430 2

414 An update on the pharmacotherapeutic options and treatment strategies for systemic sclerosis. **2020**, 21, 2041-2056 4

413 Deep Learning-based Approach for Automated Assessment of Interstitial Lung Disease in Systemic Sclerosis on CT Images. **2020**, 2, e190006 9

412 Infecciones y esclerosis sist^mica: un desaf^o emergente. **2020**, 27, 62-84

411 Relationship between calcifications and structural lesions on hand radiography and axial calcifications on CT-scan: A retrospective study in systemic sclerosis. **2020**, 99, e22443 1

410	Systemic sclerosis-associated interstitial lung disease. 2020 , 26, 487-495	1
409	Connective Tissue Disease-Related Interstitial Lung Disease: Prevalence, Patterns, Predictors, Prognosis, and Treatment. 2020 , 198, 735-759	10
408	Clinical features and long-term outcomes of Chinese patients with scleroderma renal crisis. 2020 , 23, 1194-1200	1
407	Efficacy, Safety, and Tolerability of Treatments for Systemic Sclerosis-Related Interstitial Lung Disease: A Systematic Review and Network Meta-Analysis. 2020 , 9,	7
406	Subclinical atherosclerosis in systemic sclerosis and rheumatoid arthritis: a comparative matched-cohort study. 2020 , 40, 1997-2004	3
405	The power of the EUSTAR cohort: key findings to date and implications for management of systemic sclerosis patients. 2020 , 16, 1065-1074	1
404	Mycophenolate Mofetil Improves Exercise Tolerance in Systemic Sclerosis Patients with Interstitial Lung Disease: A Pilot Study. 2020 , 7, 1037-1044	1
403	Left Ventricular Mass Index as Potential Surrogate of Muscularity in Patients With Systemic Sclerosis Without Cardiovascular Disease. 2021 , 45, 1302-1308	
402	The role of aspirin in the primary prevention of accelerated atherosclerosis in systemic autoimmune rheumatic diseases. 2020 , 59, 3593-3602	0
401	Increases in tumor markers are associated with primary Sjögren's syndrome-associated interstitial lung disease. 2020 , 11, 2040622320944802	6
400	A case of Myhre syndrome mimicking juvenile scleroderma. 2020 , 18, 72	3
399	Myopathy is a Risk Factor for Poor Prognosis of Patients with Systemic Sclerosis: A retrospective cohort study. 2020 , 99, e21734	3
398	An Update on Systemic Sclerosis and its Perioperative Management. 2020 , 10, 1-10	4
397	Le complexe antigène de carcinome à cellules squameuses-IgM (SCCA-IgM) est associé à la pneumopathie interstitielle diffuse dans la sclérodermie systémique. 2020 , 87, 472-476	
396	Infections and systemic sclerosis: an emerging challenge. 2020 , 27, 62-84	1
395	Tratamiento de la enfermedad pulmonar intersticial asociada con la esclerosis sistémica: revisión sistemática de la literatura y metaanálisis. 2020 , 27, 146-169	
394	Cancer risk in systemic sclerosis: identifying risk and managing high-risk patients. 2020 , 16, 1105-1113	1
393	Scleroderma-specific autoantibodies embedded in immune complexes mediate endothelial damage: an early event in the pathogenesis of systemic sclerosis. 2020 , 22, 265	5

392	Clinical characteristics and outcomes of 566 Thais with systemic sclerosis: A cohort study. 2020 , 23, 945-957	7
391	Rapid decrease of serum surfactant protein-D levels predicts the reactivity of rituximab therapy in systemic sclerosis-associated interstitial lung disease. 2020 , 47, 796-800	2
390	Exercise Echocardiography as a Screening Tool in Systemic Sclerosis. 2020 , 47, 643-645	1
389	Progressive lung fibrosis and mortality can occur in early systemic sclerosis patients without pulmonary abnormalities at baseline assessment. 2020 , 39, 3393-3400	3
388	A new therapy for systemic sclerosis-associated interstitial lung disease. 2020 , 58, 227-229	
387	Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease. 2020 , 16, 547-560	2
386	Renal Involvement in Systemic Sclerosis: An Update. 2020 , 45, 532-548	12
385	Thoracic lymphadenopathy as possible predictor of the onset of interstitial lung disease in systemic sclerosis patients without lung involvement at baseline visit: A retrospective analysis.. 2020 , 5, 210-218	1
384	The Role of Endogenous Eicosapentaenoic Acid and Docosahexaenoic Acid-Derived Resolvins in Systemic Sclerosis. 2020 , 11, 1249	2
383	Treatment of systemic sclerosis-associated interstitial lung disease: Lessons from clinical trials.. 2020 , 5, 61-71	26
382	Treatment modalities and drug survival in a systemic sclerosis real-life patient cohort. 2020 , 22, 56	6
381	Management of systemic sclerosis: the first five years. 2020 , 32, 228-237	15
380	Current and Future Outlook on Disease Modification and Defining Low Disease Activity in Systemic Sclerosis. 2020 , 72, 1049-1058	19
379	Cardiovascular Risk in Systemic Sclerosis. 2020 , 6, 282-298	
378	Performance Characteristics of Pulmonary Function Tests for the Detection of Interstitial Lung Disease in Adults With Early Diffuse Cutaneous Systemic Sclerosis. 2020 , 72, 1892-1896	12
377	Emerging Roles of Matricellular Proteins in Systemic Sclerosis. 2020 , 21,	4
376	Systemic sclerosis is an independent risk factor for ischemic heart disease, especially in patients carrying certain antiphospholipid antibodies: A large cross-sectional study. 2020 , 81, 44-49	0
375	Cardiovascular Risk Factors and Atherosclerotic Cardiovascular Events Among Incident Cases of Systemic Sclerosis: Results From a Population-Based Cohort (1980-2016). 2020 , 95, 1369-1378	6

374	Correlation between serological biomarkers of extracellular matrix turnover and lung fibrosis and pulmonary artery hypertension in patients with systemic sclerosis. 2020 , 23, 532-539	7
373	Cardiac Arrhythmias in Autoimmune Diseases. 2020 , 84, 685-694	12
372	Systemische Sklerose. 2020 , 19, 69-76	
371	Early trajectories of skin thickening are associated with severity and mortality in systemic sclerosis. 2020 , 22, 30	7
370	Squamous cell carcinoma antigen-IgM (SCCA-IgM) is associated with interstitial lung disease in systemic sclerosis. 2020 , 87, 331-335	5
369	Systemic sclerosis-associated interstitial lung disease. 2020 , 8, 304-320	73
368	Lung function is associated with minimal EQ-5D changes over time in patients with systemic sclerosis. 2020 , 39, 1543-1549	3
367	Systemic sclerosis: Advances towards stratified medicine. 2020 , 34, 101469	3
366	Challenges in physician-patient communication for optimal management of systemic sclerosis-associated interstitial lung disease: a discourse analysis. 2020 , 39, 2989-2998	3
365	[Illnesses unrelated to systemic sclerosis (IUSS) diagnosed throughout the patient's follow-up in a referral center: A cohort of 200 patients]. 2020 , 41, 517-522	0
364	Speckle tracking echocardiography as a new diagnostic tool for an assessment of cardiovascular disease in rheumatic patients. 2020 , 63, 327-340	5
363	Evolution of high-resolution CT-scan in systemic sclerosis-associated interstitial lung disease: Description and prognosis factors. 2020 , 50, 1406-1413	1
362	Ultrasonography involvement of carotid, upper and lower limb arteries in a large cohort of systemic sclerosis patients. 2020 , 23, 681-692	1
361	Inhibition of effector B cells by ibrutinib in systemic sclerosis. 2020 , 22, 66	14
360	Subclinical progression of systemic sclerosis-related cardiomyopathy. 2020 , 27, 1876-1886	5
359	Patient and Physician Perspectives on Systemic Sclerosis-Associated Interstitial Lung Disease. 2020 , 14, 1179548420913281	6
358	Patient-reported outcome measures in systemic sclerosis-related interstitial lung disease for clinical practice and clinical trials. 2020 , 5, 48-60	5
357	Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy. 2020 , 31, 724-744	64

356	The Challenge of Very Early Systemic Sclerosis: A Combination of Mild and Early Disease?. 2021 , 48, 82-86	8
355	Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party. 2021 , 106, 375-383	19
354	Mortality and morbidity in scleroderma renal crisis: A systematic literature review.. 2021 , 6, 21-36	3
353	Economic Burden and Management of Systemic Sclerosis-Associated Interstitial Lung Disease in 8 European Countries: The BUILDup Delphi Consensus Study. 2021 , 38, 521-540	2
352	Laser speckle contrast analysis predicts major vascular complications and mortality of patients with systemic sclerosis. 2021 , 60, 1850-1857	7
351	Disease frequency, patient characteristics, comorbidity outcomes and immunosuppressive therapy in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: a US cohort study. 2021 , 60, 1915-1925	5
350	Risk and prognosis factors for systemic sclerosis with lung cancer: A single-centre case-control study in China. 2021 , 75, e13819	0
349	Integrated bulk and single-cell RNA-sequencing identified disease-relevant monocytes and a gene network module underlying systemic sclerosis. 2021 , 116, 102547	7
348	Cultural adaptation, translation and validation of Cochin Hand Function Scale and evaluation of hand dysfunction in systemic sclerosis. 2021 , 40, 1913-1922	1
347	Elastic Registration-driven Deep Learning for Longitudinal Assessment of Systemic Sclerosis Interstitial Lung Disease at CT. 2021 , 298, 189-198	5
346	Clinical trial protocol: PRednisolone in early diffuse cutaneous Systemic Sclerosis (PRedSS). 2021 , 6, 146-153	0
345	Increased Prevalence of Moderate to Severe Mitral and Aortic Valve Dysfunction in Systemic Sclerosis: A Case-control Study. 2021 , 48, 394-401	0
344	Feasibility of online home spirometry in systemic sclerosis-associated interstitial lung disease: a pilot study. 2021 , 60, 2467-2471	1
343	Hospitalization Rates Are Highest in the First 5 Years of Systemic Sclerosis: Results From a Population-based Cohort (1980-2016). 2021 , 48, 877-882	2
342	Pulmonary Manifestations of Rheumatic Diseases in Children. 2021 , 68, 147-166	1
341	Predictors of subclinical systemic sclerosis primary heart involvement characterised by microvasculopathy and myocardial fibrosis. 2021 , 60, 2934-2945	4
340	Using quantitative computed tomography to predict mortality in patients with interstitial lung disease related to systemic sclerosis: implications for personalized medicine. 2021 , 6, 31-40	1
339	Predictive Significance of Serum Interferon-Inducible Protein Score for Response to Treatment in Systemic Sclerosis-Related Interstitial Lung Disease. 2021 , 73, 1005-1013	5

338	Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib. 2021 , 31, 13-19	6
337	Things left unsaid: important topics that are not discussed between patients with systemic sclerosis, their carers and their healthcare professionals-a discourse analysis. 2021 , 40, 1399-1407	2
336	Associated factors of early-onset pulmonary hypertension and clinical difference between early- and late-onset pulmonary hypertension in Thai systemic sclerosis. 2021 , 31, 649-656	1
335	Interstitial lung disease pathology in systemic sclerosis. 2021 , 13, 1759720X211032437	1
334	Natural history and screening of interstitial lung disease in systemic autoimmune rheumatic disorders. 2021 , 13, 1759720X211037519	2
333	Efficacy of cyclophosphamide in treating connective tissue disease-related interstitial lung diseases. 2021 , 10,	
332	CardioRheumatology. 2021 , 481-503	
331	Essential Hypertension Worsens Left Ventricular Contractility in Systemic Sclerosis. 2021 , 48, 1299-1306	1
330	Experience With Nintedanib in Severe Pulmonary Fibrosis Associated With Systemic Sclerosis: A Case Series. 2021 , 3, 100080	1
329	Pulmonary manifestations of systemic lupus erythematosus. 2021 , 521-529	
328	Increased Risk of Valvular Heart Disease in Systemic Sclerosis: An Underrecognized Cardiac Complication. 2021 , 48, 1047-1052	3
327	Identification of Autoimmunity to Peptides of Collagen V α 1 Chain as Newly Biomarkers of Early Stage of Systemic Sclerosis. 2020 , 11, 604602	3
326	Engineering Advanced In Vitro Models of Systemic Sclerosis for Drug Discovery and Development. 2021 , 5, e2000168	2
325	Evaluation of limited hand mobility in systemic sclerosis patients by using "prayer sign" and "tabletop sign". 2021 , 40, 2771-2777	0
324	Performance Under Pressure: The Relevance of Pulmonary Vascular Response to Exercise Challenge in Scleroderma. 2021 , 159, 481-483	1
323	The rationale for targeting the JAK/STAT ¹ pathway in scleroderma-associated interstitial lung disease. 2021 , 13, 241-256	6
322	Epidemiology of systemic sclerosis: a multi-database population-based study in Tuscany (Italy). 2021 , 16, 90	4
321	Are troponin and B-type natriuretic peptides useful biomarkers for the diagnosis of systemic sclerosis heart involvement? A systematic literature review. 2021 , 51, 299-309	6

320	Sepsis Mortality Is high in Patients With Connective Tissue Diseases Admitted to the Intensive Care Unit (ICU). 2021 , 885066621996257	0
319	A randomised, open-label trial to assess the optimal treatment strategy in early diffuse cutaneous systemic sclerosis: the UPSIDE study protocol. 2021 , 11, e044483	3
318	Natural variability in the disease course of SSc-ILD: implications for treatment. 2021 , 30,	7
317	⁶⁸ Ga-FAPI-04 PET-CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-associated interstitial lung disease: a single-centre, pilot study. 2021 , 3, e185-e194	9
316	Progression in the Management of Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Diseases, Where Are We Now and Where We Would Like to Be. 2021 , 10,	5
315	Interleukin-1 and Systemic Sclerosis: Getting to the Heart of Cardiac Involvement. 2021 , 12, 653950	7
314	Skleroderma hastalarında ve periodontal bulgular ile hastaların tutulumları arasındaki ilişki. 2021 , 46, 39-45	
313	Endostatin and Vascular Endothelial Growth Factor-Ab May Contribute to Classification of Pulmonary Hypertension. 2021 , 3, 161-169	2
312	Treatment for systemic sclerosis-associated interstitial lung disease. 2021 , 33, 240-248	8
311	The PREDictor of MALnutrition in Systemic Sclerosis (PREMASS) Score: A Combined Index to Predict 12 Months Onset of Malnutrition in Systemic Sclerosis. 2021 , 8, 651748	1
310	Esclerosi sistemică. 2021 , 13, 1769-1778	
309	Cardiopulmonary Exercise Testing Is an Accurate Tool for the Diagnosis of Pulmonary Arterial Hypertension in Scleroderma Related Diseases. 2021 , 14,	1
308	Circulating NT-proANP level is a predictor of mortality for systemic sclerosis: a retrospective study of an Italian cohort. 2021 , 17, 661-666	2
307	Effect of combined pulmonary fibrosis and emphysema on patients with connective tissue diseases and systemic sclerosis: a systematic review and meta-analysis. 2021 , 23, 100	1
306	Arrhythmias and Conduction Disturbances in Autoimmune Rheumatic Disorders. 2021 , 10, 17-25	5
305	Nailfold Capillaroscopy in Systemic Sclerosis Patients with and without Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. 2021 , 10,	6
304	Cardiovascular Organ Damage in Clinical Subtypes of Systemic Sclerosis: Arterial Stiffness and Echocardiography Might Not Be the Ideal Tools for Patient Risk Stratification. 2021 , 2021, 7915890	
303	Autoantibody profiles in systemic sclerosis; a comparison of diagnostic tests. 2021 , 54, 148-155	6

302	Esophageal dysmotility and lung disease in patients with systemic sclerosis: is there a possible association or correlation? A retrospective chart review. 2021 , 41, 1965-1970	0
301	Implications the Role of miR-155 in the Pathogenesis of Autoimmune Diseases. 2021 , 12, 669382	7
300	Anticentromere Antibody Levels and Isotypes and the Development of Systemic Sclerosis. 2021 , 73, 2338-2347	0
299	Estimated glomerular filtration rate and renal resistive index as possible predictive markers of mortality in systemic sclerosis. 2021 , 87, 83-89	1
298	Long term outcomes of the French ASTIS systemic sclerosis cohort using the global rank composite score. 2021 , 56, 2259-2267	2
297	Systemic sclerosis-associated interstitial lung disease treated with tocilizumab. 2021 , 51, 999-1000	0
296	Focus on progressive fibrosing interstitial lung diseases (PF-ILDs). 2021 , 8,	0
295	Anti-C1q autoantibodies may not serve as an adequate biomarker for lung manifestations in systemic sclerosis: a single-centre, cross-sectional study. 2021 , 185, 657-658	0
294	Efficacy of mycophenolate mofetil versus cyclophosphamide in systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis. 2021 , 40, 3185-3193	4
293	Rituximab as a Treatment Option after Autologous Hematopoietic Stem Cell Transplantation in a Patient with Systemic Sclerosis. 2021 , 11,	0
292	Clinical outcomes of asymptomatic cardiac involvement in systemic sclerosis patients after a 2-year follow-up (extended study). 2021 ,	0
291	Prevalence and prognostic significance of heart failure with preserved ejection fraction in systemic sclerosis. 2022 , 18, 17-25	0
290	The Prognostic Value of Cardiac Axis Deviation in Systemic Sclerosis-related Pulmonary Hypertension. 2021 ,	0
289	Mycophenolate in scleroderma-associated interstitial lung disease: Real-world data from rheumatology and pulmonology clinics in South Asia.. 2021 , 6, 271-276	0
288	Outpatient healthcare utilization among incident cases of systemic sclerosis: results from a population-based US cohort (1988-2016). 2021 , 1-6	0
287	ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part I: Epidemiology, assessment of extrapulmonary conditions, candidate evaluation, selection criteria, and pathology statements. 2021 , 40, 1251-1266	1
286	Tc-labelled glucosamine in the assessment of systemic sclerosis inflammatory lung disease: a novel inexpensive investigative tool with predictive value. 2021 , 35, 1157-1166	0
285	Prediction of a Competing Endogenous RNA Co-expression Network by Comprehensive Methods in Systemic Sclerosis-Related Interstitial Lung Disease. 2021 , 12, 633059	0

284	Systemic Sclerosis Portends Increased Risk of Conduction and Rhythm Abnormalities at Diagnosis and During Disease Course: A US Population-Based Cohort.. 2021 , 6, 277-285	0
283	A study on echocardiographic findings in hospitalized patients with connective tissue diseases. 2021 , 1-10	
282	Peripheral microcirculatory abnormalities are associated with cardiovascular risk in systemic sclerosis: a nailfold video capillaroscopy study. 2021 , 40, 4957-4968	3
281	Identification of a distal RXFP1 gene enhancer with differential activity in fibrotic lung fibroblasts involving AP-1.	
280	Outcomes linked to eligibility for stem cell transplantation trials in diffuse cutaneous systemic sclerosis. 2021 ,	1
279	An update on interstitial lung disease. 2021 , 82, 1-14	0
278	Circulating CTRP9 is Associated with Severity of Systemic Sclerosis-associated Interstitial Lung Disease. 2021 ,	1
277	Outcome measurement instrument selection for lung physiology in systemic sclerosis associated interstitial lung disease: A systematic review using the OMERACT filter 2.1 process. 2021 ,	0
276	2-Aminoethyl diphenylborinate inhibits bleomycin-induced skin and pulmonary fibrosis via interrupting intracellular Ca regulation. 2021 , 103, 101-108	0
275	Systemic sclerosis-associated pulmonary arterial hypertension in children. 2021 , 11, 1137-1143	0
274	CD19 + CD21 cells are increased in systemic sclerosis-associated interstitial lung disease. 2021 , 1	1
273	Association between gastroprotective agents and risk of incident interstitial lung disease in systemic sclerosis. 2021 , 185, 106482	
272	Cardiac calcium score in systemic sclerosis. 2021 , 1	0
271	Renal Function in Patients With Systemic Sclerosis: Do We Estimate It Correctly?. 2021 ,	
270	NT-proBNP, hs-cTnT, and CRP predict the risk of cardiopulmonary outcomes in systemic sclerosis: Findings from the Canadian Scleroderma Research Group.. 2022 , 7, 62-70	2
269	Impact of Three Different Algorithms for the Screening of SSc-PAH and Comparison with the Decisions of a Multidisciplinary Team. 2021 , 11,	0
268	Sudden Cardiac Death in Systemic Sclerosis: Diagnostics to Assess Risk and Inform Management. 2021 , 11,	0
267	Acute hospitalization in a cohort of patients with systemic sclerosis: a 10-year retrospective cohort study. 2021 , 1	0

266	Diagnostic value of cardiac natriuretic peptide on pulmonary hypertension in systemic sclerosis: A systematic review and meta-analysis. 2021 , 89, 105287	2
265	2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease. 2021 , 59, 709-740	2
264	Scleroderma Associated Interstitial Lung Disease. 2022 , 319-325	
263	Respiratory Dynamics: Function and Breath Management. 2021 , 131-144	
262	Photoacoustic and high-frequency ultrasound imaging of systemic sclerosis patients. 2021 , 23, 22	4
261	Interstitial lung disease in systemic sclerosis quantification of disease classification and progression with high-resolution computed tomography: An observational study.. 2021 , 6, 154-164	4
260	In systemic sclerosis TAPSE/sPAP ratio can be used in addition to the DETECT algorithm for pulmonary arterial hypertension diagnosis. 2021 ,	1
259	CCL2 in the Circulation Predicts Long-Term Progression of Interstitial Lung Disease in Patients With Early Systemic Sclerosis: Data From Two Independent Cohorts. 2017 , 69, 1871-1878	43
258	Interstitial Lung Disease in Systemic Sclerosis. 2015 , 379-390	1
257	Epidemiology, Environmental, and Infectious Risk Factors. 2017 , 11-24	3
256	Clinical Assessment of Lung Disease. 2017 , 363-373	1
255	Systemic Sclerosis. 2018 , 337-346	1
254	Clinical Features and Treatment of Scleroderma. 2013 , 1366-1403.e4	7
253	Effect of season on clinical outcomes of Thai systemic sclerosis: Analysis of the Thai national healthcare database. 2020 , 30, 1025-1032	3
252	Electrocardiographic markers for the prediction of ventricular arrhythmias in patients with systemic sclerosis. 2020 , 59, 478-486	5
251	Systemic sclerosis myocarditis has unique clinical, histological and prognostic features: a comparative histological analysis. 2020 , 59, 2523-2533	13
250	Systemic Sclerosis Is Associated With Increased Inpatient Mortality in Patients Admitted for Atrial Fibrillation: Analysis of the National Inpatient Sample. 2021 , 27, e477-e481	10
249	Systemic Sclerosis Is Associated With Increased Inpatient Mortality in Patients Admitted for Acute Coronary Syndrome: Analysis of the National Inpatient Sample. 2020 , 28,	8

248	Systolic and Diastolic Cardiac Functions in Juvenile Spondyloarthropathies. 2020 , Publish Ahead of Print,	1
247	Mortality in the Waikato Hospital Systemic Sclerosis Cohort. 2018 , 21, 253-260	6
246	Should patients with systemic sclerosis-related pulmonary arterial hypertension be anticoagulated?. 2013 , 43, 599-603	10
245	Systemic sclerosis in sub-Saharan Africa: a systematic review. 2020 , 37, 176	2
244	Update on Morbidity and Mortality in Systemic Sclerosis-Related Interstitial Lung Disease. 2021 , 6, 11-20	9
243	Identifying early pulmonary arterial hypertension biomarkers in systemic sclerosis: machine learning on proteomics from the DETECT cohort. 2021 , 57,	12
242	The role of pulmonary arterial hypertension-targeted therapy in systemic sclerosis. 2019 , 8,	3
241	Clinical and histopathological features of patients with systemic sclerosis undergoing endomyocardial biopsy. 2015 , 10, e0126707	66
240	Effect of bosentan in pulmonary hypertension development in systemic sclerosis patients with digital ulcers. 2020 , 15, e0243651	1
239	Classification of Pulmonary Hypertension. 2014 , 13, 17-20	1
238	Patient Perspectives in OMERACT Provide an Anchor for Future Metric Development and Improved Approaches to Healthcare Delivery in Connective Tissue Disease Related Interstitial Lung Disease (CTD-ILD). 2015 , 11, 175-183	24
237	Outcome Measures for Clinical Trials in Interstitial Lung Diseases. 2015 , 11, 163-174	23
236	Systemic Sclerosis: a Modern View on the Pathogenesis, Clinic, Diagnosis and Treatment. 2019 , 7-16	2
235	Cardiovascular disease in systemic sclerosis. 2015 , 3, 8	26
234	Epidemiology of Cancer in Systemic SclerosisSystematic Review and Meta-Analysis of Cancer Incidence, Predictors and Mortality*. 2013 , 03, 231-245	3
233	Electrical storm in systemic sclerosis: Inside the electroanatomic substrate. 2014 , 6, 1127-30	5
232	Biomarkers as an opportunity to stratify for outcome in systemic sclerosis. 2020 , 7, S193-S202	2
231	The perpetual sword of Damocles: Cardiac involvement in systemic sclerosis and the role of non-invasive imaging modalities in medical decision making. 2020 , 7, S203-S211	4

- 230 Renal Involvement in Systemic Sclerosis. 2
- 229 Lung Ultrasound for Rheumatic Diseases. **2021**, 493-527
- 228 Nintedanib in the treatment of systemic rheumatic disease-associated interstitial lung disease. **2021**, 67, 330-333
- 227 High-Resolution Computed Tomography: Lights and Shadows in Improving Care for SSc-ILD Patients. **2021**, 11, 7
- 226 Cardiovascular Manifestations of Systemic Sclerosis: An Overview of Pathophysiology, Screening Modalities, and Treatment Options. **2021**, 0
- 225 Cardiovascular outcomes in systemic sclerosis with abnormal cardiovascular MRI and serum cardiac biomarkers. **2021**, 7, 0
- 224 Systemic Sclerosis: Severe Involvement of Internal Organs. **2011**, 67-88
- 223 Pulmonary Hypertension in Older Patients. **2012**, 111-131
- 222 Kollagenosen. **2012**, 185-203
- 221 Scleroderma-systemic sclerosis. **2013**, 656-666
- 220 Musculoskeletal Syndromes in Malignancy. **2013**, 1934-1950.e6
- 219 Current and Emerging Treatment Options in Interstitial Lung Disease. **2014**, 193-216
- 218 Interstitial Lung Disease in Systemic Sclerosis. **2014**, 37-47
- 217 Immune-Mediated Inflammatory Rheumatic Diseases. **2015**, 113-132
- 216 Pulmonale Manifestationen rheumatologischer Erkrankungen. **2016**, 77-89
- 215 Cardiac Involvement: Evaluation and Management. **2017**, 331-356
- 214 TRADITIONAL RISK FACTORS FOR CARDIOVASCULAR DISEASES IN SYSTEMIC SCLEROSIS AND THEIR RELATIONSHIP TO STRUCTURAL CHANGES OF THE HEART. **2017**, 54, 687-692
- 213 Epigenetics of Systemic Sclerosis. **2017**, 1-24

212 Electrocardiographic Findings in Systemic Sclerosis. **2018**,

211 Asymptomatic left ventricular diastolic dysfunction in diffuse systemic sclerosis patients: conventional echocardiography and left atrial speckle tracking. **2019**, 46, 170-176

210 Pulmonary involvement in systemic sclerosis. **2019**, 90-105

209 Rheumatic Syndromes Related to Malignant Diseases. **2020**, 333-341

208 The relationship between global longitudinal strain and pulmonary function tests in patients with scleroderma and normal ejection fraction and pulmonary artery pressure: a case-control study. **2020**, 36, 883-888

2

207 Scleroderma as a paraneoplastic syndrome and tumors associated with scleroderma. **2020**, 14, 55-61

206 Resolving phenotypic and prognostic differences in interstitial lung disease related to systemic sclerosis by computed tomography-based radiomics.

205 Heart Failure with Preserved Ejection Fraction and Cardiomyopathy: an Under-recognized Complication of Systemic Sclerosis. **2021**, 23, 1

204 Autoantibodies from Patients with Scleroderma Renal Crisis Promote PAR-1 Receptor Activation and IL-6 Production in Endothelial Cells. **2021**, 22,

1

203 Treatment of systemic sclerosis. **2021**, 50, 104088

0

202 Beyond Scleroderma: Pulmonary Arterial Hypertension in Patients with Other Connective Tissue Diseases. **2020**, 51-60

201 RHEUMATISCHE ERKRANKUNGEN. **2020**, I-1-I8-7

200 Clinical Outcomes of Myocarditis after Moderate-Dose Steroid Therapy in Systemic Sclerosis: A Pilot Study. **2020**, 2020, 8884442

3

199 Practical Approach to Malnutrition and Weight Loss in SSc. **2021**, 243-254

198 Systemic Sclerosis-Related Myopathy. **2021**, 363-372

197 Compromiso intersticial pulmonar en la esclerosis sistémica. **2020**, 27, 36-43

196 Major Scleroderma Emergencies. **2021**, 1-14

195 Gut microbiome in systemic sclerosis: a potential therapeutic target.. **2022**, 39, 101-109

1

- 194 How did the updated hemodynamic definitions affect the frequency of pulmonary hypertension in patients with systemic sclerosis?. **2021**, 25, 30-35
- 193 QT variability index in patients with systemic sclerosis. **2019**, 6, 179-183 4
- 192 Vaccination in rheumatology: present and prospects. **2020**, 2, 44-49
- 191 Systemic Sclerosis in the Elderly. **2020**, 207-228
- 190 Nintedanib: A Potential New Therapy for Systemic Sclerosis-associated Interstitial Lung Disease. **2020**, 5, 28
- 189 An Unusual Case of Morphea in the Setting of Aplastic Anemia. **2020**, 12, e7562 1
- 188 Interstitial lung involvement in systemic sclerosis. **2020**, 27, 36-43
- 187 Is There a Link Between Nailfold Videocapillaroscopy and Pulmonary Function Tests in Systemic Sclerosis Patients?: A 24-Month Follow-up Monocentric Study. **2021**, 28, 0
- 186 Pregnancy Outcomes in Patients with Interstitial Lung Disease. **2021**, 0
- 185 Life after Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis. **2021**, 12, 951-964 1
- 184 Capillary loss reflects disease activity and prognosis in patients with systemic sclerosis. **2020**, 20, 3438-3443 3
- 183 Anti-inflammatory and immunosuppressive agents in PAH. **2013**, 218, 437-76 12
- 182 Economic burden of systemic sclerosis: systematic review. **2020**, 13, 291-303 0
- 181 Pulmonary Arterial Hypertension-A Deadly Complication of Systemic Sclerosis. **2010**, 1, 11-20
- 180 Clinical Phenotype of Endothelial Dysfunction in a Lot of Romanian Scleroderma Patients. **2015**, 10, 336-341
- 179 Clinical Phenotype of Endothelial Dysfunction in Romanian Scleroderma Patients. **2016**, 11, 26-31
- 178 The Clinical Pathophysiology of Chronic Systemic Sclerosis. **2018**, 35, 36-43
- 177 Bundle Branch Blocks and Fragmented QRS Complex in Iranian Patients with Systemic Sclerosis. **2019**, 14, 6-11

- 176 Fatal consequences of therapeutic thoracentesis in patients with systemic sclerosis. **2020**, 37, e2020006
- 175 Etiological factors of systemic sclerosis in the southeast region of Romania. **2021**, 21, 79 1
- 174 Treatment of systemic sclerosis associated ILD: Lessons from clinical trials. **2020**, 5, 61-71 12
- 173 Hospitalisations related to systemic sclerosis and the impact of interstitial lung disease. Analysis of patients hospitalised at the University of Michigan, USA. **2021**, 39 Suppl 131, 43-51
- 172 [Application of lymphocytes test in peripheral blood of patients with systemic sclerosis during the treatment]. **2021**, 53, 721-727
- 171 Anti-programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment study. **2021**, 5
- 170 Identification of Impacted Pathways and Transcriptomic Markers as Potential Mediators of Pulmonary Fibrosis in Transgenic Mice Expressing Human IGFBP5. **2021**, 22, 1
- 169 Predicting clinical events using Bayesian multivariate linear mixed models with application to scleroderma. **2021**, 21, 249
- 168 Changes in Plasma Phospholipid Metabolism Are Associated with Clinical Manifestations of Systemic Sclerosis. **2021**, 11, 0
- 167 Use of Mycophenolate Mofetil for Systemic Sclerosis and Systemic Sclerosis-Associated Interstitial Lung Disease: Information from a Japanese Hospital Claims Database. **2021**, 0
- 166 Baseline characteristics of systemic sclerosis patients with restrictive lung disease in a multi-center US-based longitudinal registry. **2021**,
- 165 Repolarization in systemic sclerosis: a meta-analysis. **2021**, 1
- 164 Myocarditis in systemic immune-mediated diseases: Prevalence, characteristics and prognosis. A systematic review.. **2022**, 21, 103037 1
- 163 Etiological factors of systemic sclerosis in the southeast region of Romania. **2020**, 21, 79 1
- 162 Cardiovascular burden in systemic sclerosis: QRISK3 versus Framingham for risk estimation. **2021**, 1
- 161 Increased Red Blood Cell Distribution Width in the First Year after Diagnosis Predicts Worsening of Systemic Sclerosis-Associated Interstitial Lung Disease at 5 Years: A Pilot Study.. **2021**, 11,
- 160 Systemic Sclerosis. **2022**, 107-135
- 159 Clinical phenotypes, hemodynamic characteristics and prognosis of Chinese patients with systemic sclerosis-associated precapillary pulmonary hypertension: a retrospective study.. **2022**, 1 1

158	Myositis-Specific Autoantibodies and QTc Changes by ECG in Idiopathic Inflammatory Myopathies.. 2022,	0
157	CXCL4 drives fibrosis by promoting several key cellular and molecular processes.. 2022, 38, 110189	6
156	Pulmonale Manifestationen rheumatologischer Erkrankungen. 2022, 83-100	
155	Heart Involvement in Systemic Sclerosis: the Role of Magnetic Resonance Imaging.. 2022, 1	0
154	The role of antifibrotic therapies in the treatment of systemic sclerosis-associated interstitial lung disease.. 2022, 14, 1759720X211066686	
153	Myocardial fibrosis and arrhythmic burden in systemic sclerosis.. 2022,	1
152	Systemic sclerosis in Asians: Are there racial differences?. 2022, 7, 98-109	0
151	Scleroderma hypertensive renal crisis among systemic sclerosis patients: A national emergency department database study.. 2022, 53, 228-235	1
150	Systemic sclerosis in adults. Part I: Clinical features and pathogenesis.. 2022,	1
149	Network based systems biology approach to identify diseasome and comorbidity associations of Systemic Sclerosis with cancers.. 2022, 8, e08892	1
148	Current Take on Systemic Sclerosis Patients' Vaccination Recommendations.. 2021, 9,	5
147	IL-13 and IL-33 Serum Levels Are Increased in Systemic Sclerosis Patients With Interstitial Lung Disease.. 2022, 9, 825567	1
146	Functional Characterization of Glycoprotein Nonmetastatic Melanoma Protein B in Scleroderma Fibrosis.. 2022, 13, 814533	0
145	Cardiac magnetic resonance in systemic sclerosis myocarditis: the value of T2 mapping to detect myocardial inflammation.. 2022,	0
144	Direct and indirect costs of systemic sclerosis and associated interstitial lung disease: A nationwide population-based cohort study.. 2022,	0
143	Peripheral blood gene expression profiling shows predictive significance for response to mycophenolate in systemic sclerosis-related interstitial lung disease.. <i>Annals of the Rheumatic Diseases, 2022,</i>	2.4 1
142	High prevalence of occult left ventricular diastolic dysfunction detected by exercise stress test in systemic sclerosis.. 2022, 12, 2423	1
141	iNKT cells can effectively inhibit IL-6 production by B cells in systemic sclerosis.. 2022,	0

140	Diastolic Dysfunction in Systemic Sclerosis: Risk Factors and Impact on Mortality.. 2021 ,	2
139	Diastolic Function Assessment of Left and Right Ventricles by MRI in Systemic Sclerosis Patients.. 2022 ,	0
138	Benefits and risks of Hematopoietic Stem Cell Transplantation for Systemic Sclerosis: A Systematic Review and Meta-Analysis.. 2022 ,	
137	Sclerodermic Cardiomyopathy-A State-of-the-Art Review.. 2022 , 12,	2
136	Cardiovascular Imaging for Systemic Sclerosis Monitoring and Management.. 2022 , 9, 846213	0
135	Clinical Overview of Progressive Fibrotic Interstitial Lung Disease.. 2022 , 9, 858339	
134	A Narrative Review of Pathogenetic and Histopathologic Aspects, Epidemiology, Classification Systems, and Disease Outcome Measures in Systemic Sclerosis.. 2022 , 1	0
133	Thoracic Involvement in Systemic Autoimmune Rheumatic Diseases: Pathogenesis and Management.. 2022 , 1	1
132	Blood neutrophil count and neutrophil-to-lymphocyte ratio predict disease progression and mortality in two independent systemic sclerosis cohorts.. 2022 ,	0
131	Incidence Rate and Prevalence of Systemic Sclerosis and Systemic Sclerosis-Associated Interstitial Lung Disease in Japan: Analysis Using Japanese Claims Databases.. 2022 , 1	2
130	Primary heart involvement in systemic sclerosis, from conventional to innovative targeted therapeutic strategies. 239719832210837	
129	An Overview of Different Techniques for Improving the Treatment of Pulmonary Hypertension Secondary in Systemic Sclerosis Patients.. 2022 , 12,	4
128	Increased risk of mortality in systemic sclerosis-associated pulmonary hypertension: a systemic review and meta-analysis.. 2022 , 62, 10	0
127	Endothelial Dysfunction in Systemic Lupus Erythematosus and Systemic Sclerosis: A Common Trigger for Different Microvascular Diseases.. 2022 , 9, 849086	1
126	Letter comments on anti-PD(L)1 immunotherapies in patients with cancer and with pre-existing systemic sclerosis: a post-marketed safety assessment study.. 2022 ,	
125	Old and new therapeutic strategies in systemic sclerosis (Review).. 2022 , 23, 134	0
124	High-Resolution Computed Tomography and Lung Ultrasound in Patients with Systemic Sclerosis: Which One to Choose?. 2021 , 11,	2
123	The Case of a Patient with Limited Systemic Sclerosis and Interstitial Lung Disease Overlapping with Systemic Lupus Erythematosus. 2021 , 1, 59-70	

- 122 Early Radiographic Progression of Scleroderma Lung Disease Predicts Long-term Mortality.. **2021**, 0
- 121 Anti-Ro/SS-A Antibody is Associated with Worse Pulmonary Outcome and Reduced Overall Survival in Systemic Sclerosis.. **2021**, 1
- 120 Management of Endothelial Dysfunction in Systemic Sclerosis: Current and Developing Strategies.. **2021**, 8, 788250 3
- 119 Sine scleroderma, limited cutaneous, and diffused cutaneous systemic sclerosis survival and predictors of mortality. **2021**, 23, 295 0
- 118 Identification of a distal RXFP1 gene enhancer with differential activity in fibrotic lung fibroblasts involving AP-1.. **2021**, 16, e0254466 0
- 117 The Role of the Multidisciplinary Health Care Team in the Management of Patients with Systemic Sclerosis.. **2022**, 15, 815-824 0
- 116 Systemic Scleroderma-Definition, Clinical Picture and Laboratory Diagnostics.. **2022**, 11, 0
- 115 Computed Tomography of the Chest to Screen for Interstitial Lung Disease in Patients With Systemic Sclerosis at Expert Scleroderma Centers in the United States.. **2022**, 0
- 114 Evaluation of Left Cardiac Chamber Function with Cardiac Magnetic Resonance and Association with Outcome in Patients with Systemic Sclerosis.. **2022**, 0
- 113 Anti-topoisomerase-positive limited systemic sclerosis has a propensity for interstitial lung disease but is linked to favorable prognosis.. **2022**, 0
- 112 Clinical, Serological, and Genetic Characteristics of a Hungarian Myositis-Scleroderma Overlap Cohort.. **2022**, 2022, 6251232 0
- 111 [Value of CT and transthoracic lung ultrasound in patients with systemic sclerosis : Joint statement of the ^ BG/^ GP/^ GR/^ GUM].. **2022**, 0
- 110 Rituximab on lung, skin, and joint involvement in patients with systemic sclerosis: A case series study and review of the literature.. **2022**, 0
- 109 Assessing the diagnostic value of a potential screening tool for detecting early interstitial lung disease at the onset of inflammatory rheumatic diseases.. **2022**, 24, 107 0
- 108 Hipertens^ˆ b pulmonar na esclerose sist^ˆ hica. **2014**, 24-27
- 107 Echocardiographic Findings in Systemic Diseases Characterized by Immune-Mediated Injury. **2017**, 692-723
- 106 Perceptions of Genetic Testing: A Mixed-methods Study of Patients with Pulmonary Fibrosis and their First-degree Relatives.. **2022**, 0
- 105 Circulating Th2 cell reduction and Th1/Th2 imbalance are correlated with primary Sjogren^ˆ syndrome-associated interstitial lung disease. **2022**, 24, 0

- 104 Altered Cellular Immunity and Differentially Expressed Immune-Related Genes in Patients With Systemic Sclerosis-Associated Pulmonary Arterial Hypertension. **2022**, 13, 0
- 103 Left Ventricular Diastolic Dysfunction in Systemic Sclerosis: Clinical, immunological and survival differences in the Spanish RESCLE Registry. **2022**, 152033 1
- 102 Lessons From Transcriptome Analysis of Autoimmune Diseases. **2022**, 13,
- 101 Use of Biologics for Systemic Sclerosis and Systemic Sclerosis-Associated Interstitial Lung Disease: Information from a Japanese Hospital Claims Database.
- 100 Zibotentan in systemic sclerosis-associated chronic kidney disease: a phase II randomised placebo-controlled trial. **2022**, 24, 2
- 99 Skin model for improving the reliability of the modified Rodnan skin score for systemic sclerosis. **2022**, 6,
- 98 Krebs von den Lungen-6 (KL-6), soluble programmed cell death-1 (sPD-1) and its ligand-1 (sPDL-1) in systemic sclerosis patients: Relation to disease parameters. **2022**, 44, 333-337
- 97 La place de l'Exploration Fonctionnelle (cardio-)respiratoire d'Exercice (EFX) dans la prise en charge de la sclérodémie systémique. **2022**,
- 96 Changes on chest HRCT in systemic sclerosis-related interstitial lung disease after autologous hematopoietic stem cell transplantation. 0
- 95 Rituximab treatment for systemic sclerosis associated interstitial lung disease: A case series of 13 patients.
- 94 Systemic sclerosis in Native Americans of the American Southwest. 1
- 93 Systemic sclerosis and tachycardia-bradycardia syndrome: a case report. **2022**, 16,
- 92 Relationship between ectopic calcifications and bone fragility depicted on computed tomography scan in 70 patients with systemic sclerosis. 239719832211044
- 91 Non-Classical HLA Determinants of the Clinical Response after Autologous Stem Cell Transplantation for Systemic Sclerosis. **2022**, 23, 7223 0
- 90 Heart Failure in Chronic Infectious and Inflammatory Conditions: Mechanistic Insights from Clinical Heterogeneity. 1
- 89 Distinct cardiovascular phenotypes are associated with prognosis in systemic sclerosis: a cardiovascular magnetic resonance study. 1
- 88 Peripheral Microangiopathy Changes in Pulmonary Arterial Hypertension Related to Systemic Sclerosis: Data From a Multicenter Observational Study. 9, 0
- 87 The Systolic Pulmonary Arterial Pressure Liaises Impaired Cardiac Autonomic Control to Pro-inflammatory Status in Systemic Sclerosis Patients. 9, 0

- 86 Prevalence and clinical associations with primary hypogonadism in male systemic sclerosis. 239719832211120
- 85 Sicca syndrome in systemic sclerosis: a narrative review on a neglected issue. ○
- 84 Drugs associated with systemic sclerosis: An updated list of suspected drugs using the WHO pharmacovigilance database. **2022**, 21, 103157
- 83 Management of progressive pulmonary fibrosis associated with connective tissue disease. **2022**, 16, 765-774 ○
- 82 Temporal Trends in Mortality in Patients with Systemic Sclerosis in Public Hospitals Across Mexico from 1998-2017. **2022**,
- 81 New Era in Systemic Sclerosis Treatment: Recently Approved Therapeutics. **2022**, 11, 4631 ○
- 80 Understanding diagnostic pathways in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: A retrospective cohort study. **2022**, 101, e29993 ○
- 79 Fibronectin-EDA Accumulates via Reduced Ubiquitination Downstream of Toll-Like Receptor 9 Activation in SSc-ILD Fibroblasts. ○
- 78 Association between CA 15-3 and progression of interstitial lung disease in a case of coexisting systemic sclerosis and recurrent breast cancer: A case report. **2022**, 17, ○
- 77 Geographical heterogeneity of clinical and serological phenotypes of systemic sclerosis observed at tertiary referral centres. The experience of the Italian SIR-SPRING registry and review of the world literature. **2022**, 21, 103159 ○
- 76 Standardized incidence ratios and risk factors for cancer in patients with systemic sclerosis: Data from the Spanish Scleroderma Registry (RESCLE). **2022**, 21, 103167 ○
- 75 Scleroderma cardiac crisis: A-life-threatening but reversible complication of systemic sclerosis. **2022**, 21, 103162 ○
- 74 Incidence, prevalence and regional distribution of systemic sclerosis and related interstitial lung Disease: A nationwide retrospective cohort study. **2022**, 19, 147997312211255 ○
- 73 Restrictive Lung Diseases in Pregnancy. **2022**, 871-888 ○
- 72 Utilidad de la ergoespirometría en el diagnóstico precoz de hipertensión pulmonar en pacientes con esclerodermia. **2022**, ○
- 71 Relationship between digital ulcers and severity of lung function test in systemic sclerosis over a five-year period. **2022**, 60, 450-454 ○
- 70 Predicting the Progression of Very Early Systemic Sclerosis: Current Insights. Volume 14, 171-186 ○
- 69 Biomarkers in Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD). 1

68	Systemic Sclerosis Associated Interstitial Lung Disease: A Conceptual Framework for Subclinical, Clinical, and Progressive Disease.	0
67	Cardiac magnetic resonance imaging before and after therapeutic interventions for systemic sclerosis-associated myocarditis.	0
66	Systemic Sclerosis Association with Malignancy.	1
65	Fibroblast activation protein imaging in non-malignant diseases: A new perspective for molecular imaging. jnumed.122.264205	0
64	Therapy satisfaction and health literacy are key factors to improve medication adherence in systemic sclerosis. 1-8	1
63	Survival and prognostic factors from a multicentre large cohort of unselected Italian systemic sclerosis patients.	0
62	The role of PET/CT in connective tissue disorders: systemic sclerosis, Sjögren's syndrome and systemic lupus erythematosus. 2022 , 66,	0
61	Mild pulmonary hemodynamic alterations in patients with systemic sclerosis: relevance of the new 2022 ESC/ERS definition of pulmonary hypertension and impact on mortality. 2022 , 23,	0
60	Arrhythmias and Conduction Disturbances in Patients with Systemic Sclerosis: A Systematic Literature Review. 2022 , 23, 12963	0
59	Prevalence and clinical association of sarcopenia among Thai patients with systemic sclerosis. 2022 , 12,	0
58	Development and validation of machine learning for early mortality in systemic sclerosis. 2022 , 12,	0
57	Increased QT dispersion and related factors in patients with systemic sclerosis. 2022 , 4, 368-373	0
56	Viewpoint: a multidisciplinary approach to the assessment of patients with systemic sclerosis-associated interstitial lung disease.	0
55	Heart disease in the course of systemic sclerosis: An observational study. 2022 , 60, 318-325	0
54	Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial. 2022 ,	4
53	Cardiac Inflammation and Fibrosis Patterns in Systemic Sclerosis, evaluated by magnetic resonance imaging: an update.. 2022 , 152126	0
52	Pulmonary Arterial Hypertension in Connective Tissue Diseases Beyond Systemic Sclerosis. 2023 , 19, 45-54	0
51	Favorable long term effects of intensified immunosuppression combined with therapeutic plasma exchange in patients with early-onset progressive systemic sclerosis-related interstitial lung disease. 2022 , 5, 100174	0

50	Systemic sclerosis. 2022 ,	2
49	Sexual Dimorphism in Interstitial Lung Disease. 2022 , 10, 3030	1
48	Different chest HRCT scan protocols change the extent of ground glass opacities. 2022 , 22,	0
47	Pathological Roles of Pulmonary Cells in Acute Lung Injury: Lessons from Clinical Practice. 2022 , 23, 15027	1
46	Die Lunge: Ausgangspunkt vieler Erkrankungen.	0
45	Patient-reported outcomes to assess dyspnoea in interstitial lung disease and pulmonary hypertension: a systematic literature review of measurement properties. 2022 , 31, 220091	0
44	The role of asymmetric dimethylarginine in endothelial dysfunction and abnormal nitric oxide metabolism in systemic sclerosis: results from a pilot study.	0
43	Sympatho-Vagal Dysfunction in Systemic Sclerosis: A Follow-Up Study. 2023 , 13, 34	1
42	Assessment of myocardial fibrosis in patients with systemic sclerosis using [68Ga]Ga-FAPI-04-PET-CT.	2
41	Transformed diffuse large B-cell lymphoma of the stomach in a patient with Sjögren's disease and systemic sclerosis: case report and literature review. 2022 , 16, 84-91	0
40	Human Regulatory T Cells: Understanding the Role of Tregs in Select Autoimmune Skin Diseases and Post-Transplant Nonmelanoma Skin Cancers. 2023 , 24, 1527	1
39	Subclinical Systemic Sclerosis Primary Heart Involvement by Cardiovascular Magnetic Resonance Shows No Significant Interval Change.	0
38	Expert consensus on the management of systemic sclerosis-associated interstitial lung disease. 2023 , 24,	2
37	The prognostic role of the echocardiographic tricuspid annular plane systolic excursion/systolic pulmonary arterial pressure (TAPSE/sPAP) ratio and its relationship with NT-proANP plasma level in systemic sclerosis. 9,	0
36	Systemic sclerosis. Part I: epidemiology, diagnosis and therapy. 2023 , 23, 66-75	0
35	Kollagenosen [Begutachtung]. 2023 , 1-4	0
34	Scleromyositis: A distinct novel entity within the systemic sclerosis and autoimmune myositis spectrum. Implications for care and pathogenesis. 13,	0
33	Responses to Exercise in Systemic Sclerosis-Associated Interstitial Lung Disease.	0

- 32 Autoimmune diseases. **2023**, 123-244
- 31 Indications plus rares de transplantation pulmonaire et circonstances particulières : la sclérodermie systémique. **2023**,
- 30 Scleroderma Systemic Sclerosis. **2023**, 712-722
- 29 Progression from suspected to definite systemic sclerosis and the role of anti-topoisomerase I antibodies. **2023**, 9, e002827
- 28 Incidence and prevalence of systemic sclerosis in Thailand in year 2017-2020: a database from the Ministry of Public Health.
- 27 Juvenile and adult-onset scleroderma: Different clinical phenotypes. **2023**, 60, 152197
- 26 Serum and bronchoalveolar lavage fluid levels of soluble B7H3 in patients with interstitial lung diseases. **2023**, 212, 107224
- 25 Computed Tomography Radiomics-based Prediction Model for Gender-Age-Physiology Staging of Connective Tissue Disease-associated Interstitial Lung Disease. **2023**,
- 24 Clinical and immunological features of patients with cancer-associated systemic sclerosis: An observational study. **2023**, 90, 105555
- 23 Differentially expressed genes in systemic sclerosis: Towards predictive medicine with new molecular tools for clinicians. **2023**, 22, 103314
- 22 Understanding and managing cardiac involvement in systemic sclerosis. **2023**, 19, 293-304
- 21 Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic Sclerosis.
- 20 Molecular Mechanisms Behind the Role of Plasmacytoid Dendritic Cells in Systemic Sclerosis. **2023**, 12, 285
- 19 First Characterization of the Transcriptome of Lung Fibroblasts of SSc Patients and Healthy Donors of African Ancestry. **2023**, 24, 3645
- 18 Cardiac involvement assessment in systemic sclerosis using speckle tracking echocardiography: a systematic review and meta-analysis. **2023**, 13, e063364
- 17 Left ventricular dysfunction and arrhythmias in asymptomatic patients with systemic sclerosis. **2023**,
- 16 Baicalein alleviates fibrosis and inflammation in systemic sclerosis by regulating B-cell abnormalities. **2023**, 23,
- 15 Cardiovascular disease and bone health in aging female rheumatic disease populations: A review. **2023**, 19, 174550572311552

- 14 Malignancies in systemic rheumatic diseases: A mini review. 14,
- 13 Risk Factors for Respiratory Failure in Patients Hospitalized With Systemic Sclerosis: An Analysis of the National Inpatient Sample. **2023**,
- 12 Clinical Trial Enrichment in Systemic Sclerosis-Associated Interstitial Lung Disease. **2023**, 163, 475-476
- 11 Impaired left-ventricular global longitudinal strain by feature-tracking cardiac MRI predicts mortality in systemic sclerosis. **2023**, 43, 849-858
- 10 Identification of Tregs-Related Genes with Molecular Patterns in Patients with Systemic Sclerosis Related to ILD. **2023**, 13, 535
- 9 Oral rehabilitation with dental implants in patients with systemic sclerosis: A systematic review. **2023**, 11,
- 8 Serum cold-inducible RNA-binding protein levels as a potential biomarker for systemic sclerosis-associated interstitial lung disease. **2023**, 13,
- 7 Role of cardiopulmonary exercise test in early diagnosis of pulmonary hypertension in scleroderma patients. **2023**, 160, 283-288
- 6 Proteomics: Potential techniques for discovering the pathogenesis of connective tissue diseases-interstitial lung disease. 14,
- 5 Cardiac involvement in systemic and local vasculitides: The value of non-invasive multimodality imaging. **2023**, 101718
- 4 Recent innovations in the screening and diagnosis of systemic sclerosis-associated interstitial lung disease. 1-14
- 3 Immune-mediated lung diseases: A narrative review. 10,
- 2 Pharmacological management of systemic sclerosis associated interstitial lung disease. 1-10
- 1 Systemic Sclerosis and the Lung. **2023**, 193-205